Method for screening a biological fluid sample for an analyte associated with proteinopathy using white light interferometry or atomic force microscopy
Patent Information
- Application Number
- HK62026124330
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-06
- Filing Date
- 2026-06-04
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480063360.8 (22) Application Date 2024.10.04 (30) Priority Data 23202249.1 2023.10.06 EP (85) PCT International Application Entering National Phase Date 2026.04.01 (86) PCT International Application Application Data PCT / EP2024 / 078080 2024.10.04 (87) PCT International Application Publication Data WO2025 / 073987 EN 2025.04.10 (71) Applicant: Hofmeister AG, Address: Basel, Switzerland (72) Inventors: M. Britzky, E. Geraint, T.M. Kiessling, M.E. Raul, P.M. Detinger, R.E. Martin, J.A. Wolfhard (74) Patent Agency: China Patent Agency (Hong Kong) Limited, 72001 Patent Attorney: Huang Tao, Lü Chuanqi (51) Int.Cl. G01B 9 / 00 (2006.01) G01N 21 / 77 (2006.01) G01N 33 / 543 (2006.01) G01Q 60 / 24 (2006.01) G01N 21 / 45 (2006.01) G01Q 60 / 42 (2006.01) (54) Invention Title: Method for Screening Biofluid Samples for Analytes Associated with Protein Diseases Using White Light Interferometry or Atomic Force Microscopy (57) Abstract: This paper discloses an apparatus and method for measuring the spatial mass distribution profile of an analyte against a crowded bioorganic material background by employing a high-frequency recognition pattern. The recognition pattern allows for Fourier filtering of mass-sensitive image data for background and noise subtraction. The apparatus and method enable the screening of biofluid samples for analytes associated with protein diseases. Claims 5 pages, Description 36 pages, Drawings 24 pages, CN 121969891 A 2026.05.01 CN 1 21 96 98 91 A 1. A method for screening a biological fluid sample for an analyte, preferably a single analyte or a mixture of analytes associated with a protein disease, the method comprising the steps of: a. providing a sensor chip (3) comprising an identification pattern (5) extending in a two-dimensional plane and having patterned elements (8) arranged thereon, at least some of the patterned elements (8) being functionalized by a molecular recognition element (10) for binding an analyte (13), the identification pattern (5) having a characteristic spatial spectrum in the plane; b.A. Provide a sensing device (10), which is or includes an imaging microscopy device (2) configured to detect a measurement signal indicating the identification pattern (5); c. Obtain the sensor chip (3) on which at least a portion of the analyte (13) of the biofluid sample has been applied; d. Image at least a portion of the identification pattern (5) to obtain image data as a function of one or two spatial measurement coordinates in the plane, digitize the image data, and determine Fourier transform image data as a function of one or two corresponding spatial frequency coordinates; e. Filter the Fourier transform image data by using the characteristic spatial spectrum of the identification pattern (5) to determine improved Fourier transform image data; and f. Transform the improved Fourier transform image data back into direct space to obtain improved image data, and thereby quantify the quality modulation contrast generated by the immobilized analyte (13). 2. The method according to claim 1, wherein obtaining the sensor chip (3) with at least a portion of the analyte (13) applied comprises providing the biofluid sample to the sensor chip (3) such that at least a portion of the analyte (13) is fixed at at least some of the molecular recognition elements (10, 11), thereby modifying the measurement signal. 3. The method according to any of the preceding claims, wherein the pattern element (8) comprises a first pattern element (8) and a second pattern element (9), particularly ridges and grooves, at least one of the first pattern element and the second pattern element (8, 9) being functionalized by the molecular recognition elements (10, 11). 4. The method according to any of the preceding claims, wherein the recognition pattern (5) comprises a plurality of different types of pattern elements (8), each type of pattern element (8) having different spatial periodicity and / or symmetry, such that the recognition pattern (5) has a corresponding plurality of characteristic spatial spectra in the plane. 5. The method according to any one of the preceding claims, wherein the characteristic spatial spectrum of the identification pattern (5) includes at least one peak region, the at least one peak region representing the pattern wavelength and / or pattern shape of the identification pattern (5). 6. The method according to any one of the preceding claims, wherein the pattern wavelength of the identification pattern (5) is selected to be shorter than the typical distance between spatial noise components originating from or arbitrarily combined with the biological fluid sample. 7. The method according to any one of the preceding claims, wherein the identification pattern (5) is at least partially composed of...A periodically repeating DNA origami structure comprising scaffold chains and staple chains is formed, the DNA origami structure providing the pattern element (8). 8. The method of claim 7, wherein the molecular recognition element is connected to the staple chain via a connector element or oligonucleotide. 9. The method of any one of claims 7 or 8, wherein the DNA origami structure comprises at least two different types of molecular recognition elements, particularly wherein the at least two different types of molecular recognition elements have different spatial periodicity and / or symmetry. 10. The method of any one of the preceding claims, wherein in step e., the improved Fourier transform image data is determined by low-pass filtering, high-pass filtering, or band-pass filtering to discard spatial noise components outside at least one peak region of the characteristic spatial spectrum of the recognition pattern (5). 11. The method according to any one of the preceding claims, wherein the identification pattern (5) has the first pattern element (8) and alternating second pattern elements (9), the first pattern element (8) being selected from: lines of functionalized sites repeatedly offset in the lateral direction; straight lines or curves of functionalized sites repeatedly offset in the lateral direction; an array of dotted functionalized sites; and combinations thereof; the second pattern element (9) being selected from: lines of gap sites; straight lines or curves of gap sites; an array of dotted gap sites; and combinations thereof. 12. The method according to any one of the preceding claims, wherein the height and / or refractive index of the identification pattern (5) is modified when the analyte is fixed. 13. The method according to any one of the preceding claims, wherein the imaging microscopy device (2) is selected from: white light interferometer (WLI), scanning probe microscope (SPM), particularly atomic force microscope (AFM) or scanning tunneling microscope (STM), electron microscope, confocal microscope, particularly laser scanning confocal microscope (LSCM), infrared microscope, Raman spectrometer, phase contrast microscope, and combinations thereof. 14. The method according to any one of the preceding claims, wherein in step a. the method provides a multiplexed sensor chip (3), the multiplexed sensor chip (3) comprising a plurality of identification patterns (5), the plurality of identification patterns (5) preferably arranged at different locations on the sensor chip (3), particularly, a particular identification pattern (5) is characterized by at least one of the following: specific functionalization of at least one first pattern element or second pattern element (8, 9) for combining one or more specific analytes (13); a specific characteristic spatial spectrum in the plane; the identification pattern (5) on the sensor chip (3)15. The method according to any of the preceding claims, wherein the imaging microscopy device (2) is a white light interferometer (WLI) that operates under reflection and includes an imaging detector having a linear or planar pixel array configured to acquire interferometric image data containing phase-sensitive information for determining the height and / or refractive index distribution of the identification pattern (5) and thereby determining the mass modulation generated by the immobilized analyte (13). 16. The method according to any of the preceding claims, wherein the imaging microscopy device (2) is a scanning probe microscope, such as a scanning force microscope, the scanning probe microscope including a cantilever or cantilever array configured to perform contour analysis on the plane to obtain AFM image data containing AFM feature information for determining the atomic or molecular height contour of the pattern and thereby determining the mass modulation generated by the immobilized analyte (13). 17. The method according to any one of the preceding claims, wherein the functionalization is based on: the molecular recognition element, in particular the antibody, providing chemical specificity to bind at least one specific analyte (13) associated with a protein disease, and / or being configured to bind a specific epitope of the analyte (13) associated with a protein disease, and / or being configured to bind the analyte or the epitope of the analyte associated with a protein disease with specific binding affinity. 18. The method according to any one of the preceding claims, wherein the first patterning element (8) is configured to bind a first analyte, the second patterning element (9) is configured to bind a second analyte, and the sensing device (10) is configured to quantify the difference between the mass modulation contrast generated by immobilizing the first analyte and the immobilized second analyte. 19. The method according to any one of the preceding claims, the method further comprising the steps of: determining parameters of the analyte (13) associated with the protein pathogenesis from a quantified mass modulation contrast and optionally time; and / or determining parameters of: aggregates of the analyte (13) associated with the protein pathogenesis, or co-aggregates containing the analyte (13) associated with the protein pathogenesis, from the quantified mass modulation contrast and optionally time. 20. The method according to claim 19, the method further comprising the step of: determining the presence of the aggregates or co-aggregates from the determined parameters, particularly wherein if the determined parameters are within a predefined incubation time.If a predetermined threshold is exceeded, the presence of the aggregate or co-aggregate is determined; and preferably, determining the presence of the aggregate or co-aggregate includes comparing the determined parameter with a reference parameter, such as a reference parameter obtained from different patient groups or from healthy subjects, or a previous parameter of a subject from which the biofluid sample has been obtained. 21. The method according to any one of the preceding claims, wherein the analyte associated with the protein disease comprises one or more of the following: β-amyloid protein, tau, α-synuclein, prion protein, sarcoma fusion protein, wild-type or mutant polyQ huntingtin protein, ubiquitin, ataxin-3, Optineurin, TAR DNA-binding protein 43, neurofibrillary light chain (NfL), soluble or exfoliated trigger receptor 2 (sTREM2) expressed on myeloid cells, chitinase-3-like protein 1, glial fibrillary acidic protein, and truncated or other post-translational modified forms of these proteins. 22. The method according to any one of the preceding claims, wherein step d. is performed during a measurement time, and the image data is measured as a function of the measurement time to determine aggregation behavior, particularly the aggregation of additional material in the biofluid sample, such as any residual biological material, e.g., cellular components, mitochondria, cell membranes, nucleic acids, proteins, and fragments thereof; or step d. includes single-point measurements at specific time points, particularly steady-state measurements. 23. The method according to any one of the preceding claims, wherein a rinsing step is performed after step c. and particularly before or during step d, and / or wherein a processing step is performed after step b, the processing step preferably comprising applying a processing agent, such as a detergent selected from: ionic agents, solvents, acids, bases, aggregate stabilizers, aggregate destabilizers, and combinations thereof. 24. The method according to any one of the preceding claims, wherein after step b., a seed amplification assay is performed by adding a binding reagent sample, particularly a protein sample, to the identification pattern (5). 25. The method according to any one of the preceding claims, wherein the method further comprises a secondary characterization step for characterizing the state of the analyte (13) associated with the proteopathic disease or aggregates or co-aggregates formed by the analyte (13) associated with the proteopathic disease, wherein the secondary characterization step preferably comprises ELISA, FT-IR, Raman, or fluorescence spectroscopy; particularly wherein the secondary characterization step is performed directly on the biofluid sample already provided to the identification pattern (5). 26. The method according to any one of the preceding claims, wherein the signal shape measured in steps c. and d.An immune signature is generated for the biological fluid sample; specifically, the immune signature of the biological fluid sample is compared with a database of immune signatures of multiple samples, such as patient samples, autologous patient samples and / or reference samples, wherein the immune signatures in the database are preferably each associated with a clinical state of a protein disease. 27. A screening device (1) for screening a biological fluid sample for an analyte, particularly for a device (1) for performing the method according to any one of the preceding claims, the device (1) comprising: a. a sensor chip (3) including an identification pattern (5) extending in a two-dimensional plane and having patterned elements arranged thereon, at least some of the patterned elements (8) being functionalized by a molecular recognition element (10) for binding an analyte (13), the identification pattern (5) having a characteristic spatial spectrum in the plane; b. a sensing device (10) being or including an imaging microscopy device (2) configured to detect a measurement signal indicating the identification pattern (5) and to detect a modified measurement signal that has been modified because at least a portion of the analyte (13) of the biological fluid sample has been applied thereon to the sensor chip; c. The sensing device (10) includes: an imaging unit (2) for imaging at least a portion of the identification pattern (5) to obtain image data as a function of one or two spatial measurement coordinates in the plane; and a processor (41) configured to digitize the image data and to determine Fourier transform image data as a function of one or two corresponding spatial frequency coordinates; d. The sensing device (10) further includes: a processor (41) configured to improve the Fourier transform image data by filtering the Fourier transform image data using the characteristic spatial spectrum of the identification pattern (5); and e. The processor (41) configured to re-transform the improved Fourier transform image data into direct space to obtain improved image data and is configured to thereby quantify the quality modulation contrast generated by the immobilized analyte. 28. The screening device (1) according to claim 27, wherein the sensing device (10) further comprises a sampling unit for providing the biofluid sample to the sensor chip (3), such that the analyte (13)The portion is fixed at at least some of the molecular recognition elements (8, 9) to modify the measurement signal. 29. The screening device (1) according to any one of claims 27 or 28, wherein the pattern element (8) comprises a first pattern element (8) and a second pattern element (9), particularly ridges and grooves, at least one of the first pattern element and the second pattern element (8, 9) being functionalized by the molecular recognition element (10, 11). 30. The screening device (1) according to any one of claims 27 to 29, wherein the recognition pattern (5) comprises a plurality of different types of pattern elements (8), each type of pattern element (8) having a different spatial periodicity, such that the recognition pattern (5) has a plurality of corresponding characteristic spatial spectra in the plane. 31. The screening device (1) according to any one of claims 27 to 30, wherein the processor (41) is configured to filter the Fourier transform image data for relative enhancement in a selected region, particularly in a narrow spatial frequency range, wherein the pattern of the identification pattern (5) has characteristic spatial frequency peaks representing the pattern period and / or pattern shape of the identification pattern (5). 32. The screening device (1) according to any one of claims 27 to 31, wherein on the sensor chip (3), the pattern wavelength of at least one identification pattern (5) is selected to be shorter than the typical distance between spatial noise components originating from or arbitrarily associated with the identification pattern (5) in the biological fluid sample. 33. The screening device (1) according to any one of claims 27 to 31, wherein the identification pattern (5) is at least partially formed by a periodically repeating DNA origami structure comprising scaffold chains and staple chains, the DNA origami structure providing the pattern element (8). Claims 4 / 5, page 5, CN 121969891, A 34. The screening device (1) according to claim 33, wherein the molecular recognition element is connected to the staple chain via a connector element. 35. The screening device (1) according to any one of claims 33 or 34, wherein the DNA origami structure comprises at least two different types of molecular recognition elements, particularly wherein the at least two different types of molecular recognition elements have different spatial periodicities. 36. The screening device (1) according to any one of claims 27 to 35, wherein the recognition pattern (5) has a first pattern element (8) and alternating second pattern elements (9), the first pattern element (8)Selected from: lines of functionalized sites that are repeatedly offset in the lateral direction; straight lines or curves of functionalized sites that are repeatedly offset in the lateral direction; arrays of dot-like functionalized sites; and combinations thereof; the second pattern element (9) is selected from: lines of gap sites; straight lines or curves of gap sites; arrays of dot-like gap sites; and combinations thereof. 37. The screening device (1) according to any one of claims 27 to 36, wherein the sensor chip (3) is multiplexed to include a plurality of identification patterns (3), the plurality of identification patterns preferably arranged at different locations on the sensor chip (3), particularly, a particular identification pattern (5) is characterized by at least one of the following: specific functionalization of at least one first pattern element or second pattern element (8, 9) for combining one or more specific analytes (13); a specific characteristic spatial spectrum in the plane; a specific positioning of the identification pattern (5) on the sensor chip (3); a specific arrangement of the identification pattern (5) on the sensor chip (3), for example, in a rectangular or square array. 38. The screening apparatus (1) according to any one of claims 27 to 37, wherein the imaging microscopy device (2) is a white light interferometer (WLI), the white light interferometer operating under reflection and comprising an optical imaging detector having a linear or planar pixel array, the optical imaging detector being configured to acquire interferometric image data containing phase-sensitive information for determining the height and / or refractive index distribution of the identification pattern (5) and thereby determining the mass modulation generated by the immobilized analyte (13). 39. The screening apparatus (1) according to any one of claims 27 to 38, wherein the imaging microscopy device (2) is a scanning atomic force microscope (AFM), the scanning atomic force microscope comprising a cantilever or cantilever array configured to scan across the plane to acquire AFM image data containing AFM feature information for determining the atomic or molecular height profile of the identification pattern (5) and thereby determining the mass modulation generated by the immobilized analyte (13). 40. A sensor chip (10) specifically designed for use with a screening device (1) according to any one of claims 27 to 39 or for use in a method according to any one of claims 1 to 26, the sensor chip comprising a recognition grating comprising a DNA origami structure functionalized with molecular recognition elements for binding analytes, the molecular recognition elements forming substantially periodic patterns. Claims 5 / 5 pages 6 CN 121969891 AMethod for Screening Biological Fluid Samples for Analytes Associated with Protein Diseases Using White Light Interferometry or Atomic Force Microscopy
[0001] This invention relates to the field of analysis of biological fluid samples, and particularly to the field of protein diseases. This invention relates to a method for screening biological fluid samples for analytes associated with protein diseases. Background Art
[0002] Screening biological samples for various analytes is crucial in the fields of diagnostics, as well as in drug and biomarker discovery or in monitoring biotechnology. Molecular biological processes are built on the selective recognition of molecules. Recognition processes are often associated with spatial variations in mass as recognizing molecules form novel and differently sized complexes. Evolution has tuned molecular recognition in cells and organisms to be selective as they compete with random particles in complex and chaotic environments. Biological samples are crowded with non-selective and competitively binding molecules, but recognizing entities can be scarce. Recognizing molecules can be proteins, small molecules, oligonucleotides, lipids, metabolites of many other proteins and many other proteins, small molecules, oligonucleotides, salts, and water.
[0003] In terms of analysis, measuring the participation of a recognition molecule in an environment crowded with many other molecules is challenging, especially because specific and non-specific interactions cannot be adequately distinguished from each other. A prerequisite or requirement for such measurements is a selective recognition element that recognizes or “captures” the molecule. The captured molecule must have a high affinity for the target analyte. The formation of a binding complex due to the recognition interaction between the captured molecule and the corresponding analyte generates novel particles or compounds with physical properties different from those of the captured molecule or the analyte alone. For example, their volume, density, mass, and / or optical properties may differ. However, these differences may be small and therefore difficult to measure in cases where the environmental background is crowded with comparable particles, as these comparable particles or compounds introduce binding noise due to non-specific interactions and random diffusion. Such noisy environmental backgrounds are found in typical biological samples.
[0004] Focal molography is a known biosensor technique that overcomes this challenge. It is an optical biosensor capable of detecting analytes in complex binding media. It is based on the principle of spatially locked amplification. A two-dimensional affinity grating is central to this technique, in which recognition elements are arranged alternately to form a grating that is patterned similarly to a diffractive lens. Mass modulation on the grating is achieved due to selective binding events with the analyte, leading to cooperative amplification of the resulting signal. Coherent light (e.g., from a laser source with a defined wavelength that diffracts at different locations on the affinity grating (diffractive recognition lens)) is focused or concentrated at a single focal point, and the backscattered light measured at that point...The intensity of the scattered light overcomes the random scattering caused by binding events that equally affect the entire sensor surface. The physical constraint of this detection principle is that the pattern structure and periodicity of the affinity grating must coherently match the wavelength of the laser; therefore, the cell size of the affinity grating may not change freely. Thus, the size and mass of the analyte cannot exceed one-quarter of the wavelength of the light. On the other hand, if the grating is finer, the sensitivity of this detection principle for very small analytes will increase.
[0005] In various protein diseases, the formation of amyloid proteins is accompanied by a structural transition from helical or randomly coiled monomers to aggregated oligomers with a higher β-lamellae content. This transition can be measured using infrared adsorption spectroscopy. Biofluids derived from Alzheimer's patients in a very early stage of the disease have revealed amide-band adsorption profiles different from those of healthy controls. (Page 1 / 36, CN 121969891 A) Infrared biosensors equipped with molecular recognition elements targeting marker proteins in proteopathies are entering clinical trials; however, they require large sample volumes, and the selective and non-selective recognition of analytes is not easily distinguishable from each other, which reduces the value of the approach.
[0006] Proteopathies are a group of diseases that can affect the entire body. In the brain or peripheral nervous system, they are characterized by the accumulation of pathological extracellular or intracellular proteins. Pathology can be analyzed in the brain post-mortem or in peripheral tissues during biopsy. The temporal and spatial distribution and abundance of proteopathies are used for disease staging and post-mortem confirmation in clinical diagnosis. In some neurodegenerative diseases, the order of proteopathic appearance follows neuroanatomical connections throughout the nervous system. This observation proposes the hypothesis that certain pathogenic species of the proteins involved (in some cases referred to as 'pathogenic seeds') may spread between neurons in a time-dependent and region-specific manner, leading to neuronal-to-neuronal propagation and pathological development. Some proteins and their different protein forms generated during the pathogenic process can reach body fluids, such as cerebrospinal fluid or blood. It is hypothesized that pathogenic seeds are also present in other body fluids. Neuropathological markers are associated with synaptic and global neuronal dysfunction and eventual neuronal loss. Neuropathology is also accompanied by abnormally regulated local innate immune cells, a process that may manifest as neuroinflammation in some cases. Synchronous and persistent damage to brain structure and function can occur over decades and is reflected in non-motor functions (i.e., cognition and overall social behavior) and, in some diseases, in the currently uncontrollable deterioration of motor function. The early stages of neurodegeneration and the development of protein disorders often occur unnoticed over several years. This is due to early symptoms.Often insidious or undetectable, initially not specific to a disease, and lacking observable "major symptoms," the pre-diagnostic stage of disease is considered "preclinical" or prodromal if the likelihood of disease development is high based on preclinical symptoms. Early and clear detection of the preclinical stage and differentiation of potential disease trajectories will help identify patients and improve the diagnosis of novel therapies for upcoming neurodegenerative diseases. Furthermore, it is expected to allow for better classification and stratification of patients into clinical subtypes and monitoring of disease progression and treatment effectiveness.
[0007] The brains of patients with Alzheimer's disease, Parkinson's disease, Huntington's disease, or other related neurodegenerative protein disorders are scattered with abnormal protein cellular inclusions. Similar inclusions can also be found in the peripheral nervous system in some diseases, and some of their proteins or peptide fragments accumulate in the extracellular space of the brain, forming so-called plaques (e.g., in Alzheimer's disease, they are called senile plaques or amyloid plaques). Such pathogenic proteins have been drug targets and diagnostic biomarkers for decades in terms of analysis and treatment. Analysis of brain tissue and exploration of disease mechanisms in cell culture and in vivo model systems have shown that disease-associated proteins undergo aberrant metabolic and post-translational modifications and accumulate into poorly soluble fractions, which may be complex biochemical substances reaching micrometer-scale sizes and becoming crowded with poorly degradable substances, often exhibiting oligomeric, protofibrillary, fibrous, or aggregated protein assemblies. The cellular inclusions of these proteins may contain collapsed organelles, lipid vesicles, and other unspecified cellular structures and substances.
[0008] Therefore, these pathological features (which may be analytes associated with protein diseases) are highly diverse and heterogeneous. Analysis of the composition of cellular inclusions and plaques in the brain is only possible post-mortem. Data from human tissues and model systems indicate a multifactorial contribution to the development of protein diseases, including maturation over extended periods based on certain intrinsic factors (i.e., genetic susceptibility, aging process) or due to extrinsic triggers (i.e., viral or bacterial infection, toxins), and the accumulation of specific proteins due to overproduction or dysfunctional clearance mechanisms or lipid turnover. Abundant proteins can reach high local or subcellular concentrations, and therefore have a higher chance of accumulating and becoming part of the pathological markers of different protein diseases. Multifactorial etiology, the development of multiple protein diseases within the same disease spectrum, and the inability to obtain biological samples most closely resembling the neurodegenerative process (i.e., directly from the brain of a living person) worsen the situation for accurate diagnosis and treatment selection at the individual patient level.
[0009] Brain imaging during the disease process using specific radiotracers (i.e., by positron emission tomography, PET) has so far detected only one type of protein inclusion body (i.e....Tau tangles and extracellular amyloid β-plasms. Some proteins or protein forms that cause protein diseases can be specifically detected and quantified in body fluids (such as blood or cerebrospinal fluid) by immunoassay or mass spectrometry. To date, only a very small number of specific monomeric β-amyloid peptides and Tau protein forms have been identified, which has become a support for clinical diagnosis based on biomarkers. Detection of a single aggregated form of a protein by immunoassay is currently insufficient for proper validation and qualitative analysis, or lacks sufficient sensitivity and specificity as a diagnostic marker. Other approaches have proposed detecting aggregated proteins in biological fluids using so-called seed amplification assays. In this method, the biological fluid is suspected of containing protein aggregates associated with a specific protein disease, and it can act as a seed to trigger the aggregation of a monomeric recombinant form of the same protein, which is added as a substrate to the amplification process. Aggregates amplified in vitro are typically detectable by amyloid-specific fluorescent dyes. To date, this assay has shown low reproducibility between laboratories, assay performance allows only qualitative readings, and the assay requires several days of processing and incubation. In summary, this makes it difficult to develop current seed amplification assays into diagnostic assays.
[0010] From a technical perspective, a prerequisite for currently known methods of screening for protein diseases is the selective staining or labeling of molecular entities rich in marker proteins. Detecting aggregated protein forms is challenging and requires molecules selective for such substances due to the abundance of competing monomeric forms. Aggregates that underlie protein diseases can be unpredictably complex and form clumps with other proteins, lipids, and collapsed organelles, as mentioned above. In addition to the general and technical challenges mentioned above (such as nonspecific particle interactions, molecular crowding, and diffusion in biological fluids), this fact makes it particularly difficult to achieve selectivity for aggregates relative to monomers in biological fluids, especially in Parkinson's disease. The failure of known PET tracer projects to date and the lack of biomarkers support the view that known methods cannot adequately distinguish between aggregated and non-aggregated substances.
[0011] The dissociation constants of intrinsically disordered proteins, which serve as recognition elements for antibodies and other molecular entities, typically have nM (nanomolar) affinity. Structured epitopes and / or targets with multiple binding sites can achieve pM (picomolar) affinity. Well-structured oligomers and coherently assembled fibrils are examples of this. However, not all antibodies targeting aSYN aggregates tested in Parkinson's disease (PD) are able to distinguish patients from controls in biofluids, at least according to established detection principles. This observation may be related to: 1) an unfavorable concentration ratio of aggregates to monomers in the study group; 2) non-specific binding and lack of detection sensitivity in biofluids by applying physical detection principles; 3)The generally low abundance of the target epitopes, and / or 4) the wider spatial structure and structural complexity of the target aggregates. Published data indicate that the concentration range (here referring to the concentration or amount of the target epitope) matches the affinity selectivity limitations of all recognition elements (such as antibodies) established to date. Seed amplification assays are the only method capable of distinguishing PD patients from healthy controls. Interestingly, this assay does not require antibodies or other recognition elements in the first place, as it measures the nucleation potential of a large fluid volume, and trace amounts of seeds are known to be sufficient to initiate the amplification process.
[0012] However, ideally, aggregates and co-aggregates associated with protein diseases would be detected as analytes in readily available biological fluids without the need for complex tissue sampling (especially human brain tissue, which is primarily sampled post-mortem), and a method would be applied to study and identify analytes in undisturbed biological fluids.
[0013] Biomarkers other than aggregated proteins and based on pathological metabolite and / or RNA concentration profiles are gaining interest in this field. Detection of these in biological fluids is challenging because they are rare and / or the analytes are small molecules, making it difficult to locate them in a label-free manner based on their physical properties. Only methods that achieve single-molecule sensitivity and experiments that adequately suppress noise (e.g., due to nonspecific binding) have the potential to achieve this, such as atomic force microscopy or electron microscopy.
[0014] Bacteria, organelles, supramolecular assemblies, or aggregated proteins in proteopathies are large particles and not necessarily compatible with the size of laser-based diffraction sensors. Suitable and scalable high-quality recognition patterns can be generated at all frequencies using photolithography, and mass modulation resulting from analyte binding can be read out using optical interferometers. Lateral resolution is still limited by the applied wavelength; however, the vertical resolution of the interferometer can reveal atomic mass variations. Therefore, optical interferometry is suitable for large patterns and larger analytes. Commercial interferometers already have a high degree of automated acquisition and can measure many different gratings in a short time. Mass modulation associated with the affinity of selected or explored recognition elements and trapping molecules can be validated in high throughput; used to support drug and biomarker discovery, or to identify the most effective recognition elements in diagnostics.
[0015] EP2872478 A1, published on September 1, 2021, under the name of ETH Zürich, discloses a diffraction measurement biosensing device for analyzing molecular interactions using coherent lasers. The device includes a 3D transparent carrier medium with a grating structure having multiple continuous curved surfaces or lines arranged in...Multiple binding sites are present on the grating structure. These binding sites are configured to interact with one or more target molecules. The grating structure is configured to diffract a portion of coherent light propagating in the carrier medium to generate a constructive interference signal at the photodetector, which depends on molecular interactions at or near the binding sites. The curved surface can be a parabola of a plane wave focusing incident coherent light, or a sphere or ellipsoid of a spherical wave focusing incident coherent light, or arranged to diffract the incident plane wave of coherent light to a planar surface in 3D in a predetermined direction. The surface of the grating structure is patterned onto the carrier medium photolithographically using interference lithography or multiphoton lithography. Grating structures with multiple 2D or 1D surfaces or lines can be arranged in a waveguide or its evanescent field region and act as distributed Bragg reflectors. Multiplexing can be achieved using several grating structures that are spatially separated or overlapped with different periodicities to provide different diffraction angles. Different grating structures can be functionalized in different ways to identify different analytes. Such diffraction measurement sensing devices have the following disadvantages: coherent light is required for readout, and preferably propagation in one or more waveguides is required to confine the light to increase the detection signal, and dark field illumination is required to minimize scattering from any unpatterned volume.
[0016] A. Palermo et al., “Vertical Scanning Interferometry for Label-Free Detection of Peptide-Antibody Interactions”, published on 2019-03-27 in High-Throughput (http: / / dx.doi.org / 10.3390 / ht8020007), disclosed that vertical scanning interferometry (VSI) can be applied to measure the interaction of peptides with certain antibodies in serum in high throughput. The peptide array on the surface is incubated with a biological fluid and washed with DPBS for analysis with VSI. Due to the change in refractive index, the immobilized analyte induces a mass-dependent change in the interfacial reflectance. The resolution and quantification of this method were validated by morphological analysis of the immobilized analyte surface using atomic force microscopy (AFM). The VSI technique was able to analyze an array area of 5.1 square millimeters in 3 to 4 minutes with a resolution of 1.4 μm laterally and 0.1 nm vertically in fully automated mode.
[0017] J.K. Barrows et al., “Biolayer interferometry for DNA-protein interactions”, PLOS ONE, published on 2022-02-02.(https: / / doi.org / 10.1371 / journal.pone.0263322) discloses Biolayer Interferometry (BLI) as a widely used technique for real-time determination of macromolecular interaction dynamics. By using changes in the interference pattern of white light reflected from the tip of a biosensor, BLI can determine binding parameters for protein-protein (e.g., antibody-substrate kinetics), protein-small molecule (e.g., drug discovery), or DNA-protein interactions. BLI analyzes the differences in the interference patterns of white light reflected from a reference layer and a biolayer. The biolayer is coupled to a target molecule and then introduced into a solution containing other target molecules. The interaction between free and stationary molecules alters the interference pattern, resulting in a change in the optical wavelength measured in real time. These data are then used to determine association and dissociation rates using scientific plotting and statistical software (e.g., GraphPad Prism software).
[0018] G. Sancho-Fornes et al., “Enhancing the sensitivity in optical biosensing by striped arrays and frequency-domain analysis”, Sensors & Actuators: B. Chemical 281 (2019), pp. 432-438, disclose an optical biosensor based on patterned strips of biochemical probes and frequency-domain analysis (FDA)-based signal processing. FDA relies on patterning biometric assays on a solid matrix into straight and equidistant strips, which generate periodic signals when scanned by a laser beam from a DVD drive controlled by custom software. The focused laser beam follows a helical trajectory at a linear velocity and absorbs and scatters light when it strikes an immunoreaction product. The drive converts the analog signal into a binary signal, which is arranged as an image in a computer. Interaction with the immunoreaction product causes variations in the intensity of the reflected laser beam, and the light attenuation is related to the analyte concentration. In FDA analysis, periodic signals are unified into a single frequency peak by: transforming them to their frequency counterparts using a Fourier transform; averaging them in the frequency domain; using the height of the resulting peak as the analytical signal to suppress unwanted contributions propagating along the spectrum; and transforming the analytical signal back into direct space to visualize the resulting FDA peak centered on the periodic value of the striped biometric assay pattern. For striped patterning of the biometric assays required by the FDA, the incubation mask is made of a silicone-free adhesive plastic film and contains relatively wide striped cavities attached to the assay substrate.The signal-to-noise ratio is higher than that of the original or digitally filtered microarray method.
[0019] US5398113, published on March 14, 1995, under the name of Zygo Corporation, discloses an optical system for measuring the morphology of an object. The system includes an interferometer with a multicolor or white light source, a mechanical scanning device for changing the optical path difference between the object and a reference surface, a two-dimensional detector array, and a digital signal processing device for determining the surface height from the interferometric data. By scanning the object in a direction generally perpendicular to the illuminated object surface, while simultaneously recording detector data in a digital memory, an interferogram for each detector image point in the field of view is generated simultaneously. These interferograms recorded for each image point as a function of the scanning height are then transformed into the spatial frequency domain by Fourier analysis, and the surface height for each corresponding object surface point is obtained by examining the complex phase as a function of the spatial frequency. A complete three-dimensional image of the object surface is then constructed from the height data and the corresponding image plane coordinates. In this system, fringe contrast is never calculated, and the analysis occurs entirely in the spatial frequency domain.
[0020] EP3404356A1, published on November 21, 2018, under the name of NTN Corporation, discloses a method for measuring the volume of a microscopic projection (such as a droplet) using white light interferometry. A Mirau-type interferometer includes a lens, a reference mirror, and a beam splitter for splitting white light emitted from a light source into two beams, one illuminating the surface of an object and the other illuminating the reference mirror, and for recombinating the beams reflected from the object surface and the reference mirror to interfere with each other. Using a white light source, the intensity of the interference light is maximized only at the focal point of the Mirau-type interferometer, unlike when using a single-wavelength light source (such as a laser). This allows for the measurement of the three-dimensional shape of the droplet. The Mirau-type interferometer, along with the optional substrate itself, is moved up and down to generate multiple images with variable interference modulation contrast for each pixel location x, y in the droplet plane. For each pixel, the height position of the envelope of the interference intensity peaks in the multiple images is determined, and the height of the droplet is detected by comparison with a reference plane region outside the droplet region. In the outer circumference of the droplet, the droplet curvature reduces reflection along the optical axis, the modulation contrast drops below the threshold, and the diameter of the droplet is thus determined. Finally, the volume of the droplet is calculated. Michelson or Riniku type interference objectives can be used instead of Mirau type interference objectives.
[0021] WO2018 / 102398A1, published on June 7, 2018, under the name of Nanometrics Incorporated.A scanning white light interferometry system for characterizing patterned semiconductor features is disclosed. The electric field, rather than the intensity, can be extracted from the interferometric data by performing a Fourier transform on the interferometric data at each pixel (page 5 / 36 of the specification, CN 121969891 A). One or more features of the sample, such as height differences at different locations on the sample surface, can be determined based on the electric field and an electric field model, which are functions of the azimuth, incident angle, and wavelength at zero diffraction order.
[0022] US5874668, published on February 23, 1999, under the name of Arch Development Corporation, discloses a scanning probe microscope (SPM), particularly an atomic force microscope (AFM) or scanning tunneling microscope (STM), for biological samples. The AFM may include subsystems such as electrostatic microscopes, electrical probe microscopes, or ultrasoft microscope probes. A biospecific molecule is incorporated into the cantilever tip, which is directly attached to or indirectly attached to the scanning probe tip via an intermediate gold particle. The AFM image is generated by the interaction between the functionalized tip and the biological sample or environment. In particular, biospecific molecules can recognize specific sites, for example, on receptors or antibodies. Dynamic AFM imaging has been used, for example, to observe the formation of antigen-antibody complexes.
[0023] DE102010026703 B4, published on January 12, 2021, under the name of Technische Universität Illmenau, discloses an atomic force microscope (AFM) with multiple cantilever arms. Each cantilever arm has an integrated piezoresistive sensor, a measurement tip, a dynamic actuator electrically coupled to all cantilever arms, and a separately controllable static actuator. AFM can be used to scan biological surfaces. In biosensing applications, the presence of biological media causes a change in the mass of the functionalized cantilever tip, which can be measured by detecting amplitude, frequency, or phase. Summary of the Invention
[0024] The object of the present invention is to provide an improved apparatus and method for screening biofluid analytes, such as analytes associated with protein diseases. This object is achieved by the subject matter set forth in the independent claims. Some embodiments are given in the dependent claims and combinations thereof and in the specification, and further improvements may be provided.
[0025] The present invention relates to a method for screening a biological fluid sample for an analyte, preferably a single analyte or a mixture of analytes associated with a protein disease, the method comprising the steps of: a. providing a sensor chip comprising a recognition pattern extending in a two-dimensional plane and having patterned elements arranged thereon, at least some of the patterned elements being functionalized with molecular recognition elements for binding to molecules.The steps are as follows: a. Analyzing the pattern to identify it having a characteristic spatial spectrum in a plane; b. Providing a sensing device, which is or includes an imaging microscopy device configured to detect a measurement signal indicating the identification pattern; c. Obtaining a sensor chip to which at least a portion of the analyte of the biological fluid sample has been applied; d. Imaging at least a portion of the identification pattern to obtain image data as a function of one or two spatial measurement coordinates in a plane, digitizing the image data, and determining Fourier transform image data as a function of one or two corresponding spatial frequencies and / or spatial wave vector coordinates; e. Determining improved Fourier transform image data by filtering the Fourier transform image data using the characteristic spatial spectrum of the identification pattern; and f. Transforming the improved Fourier transform image data back into direct space to obtain improved image data, and thereby quantifying the quality modulation contrast generated by the immobilized analyte.
[0026] In one embodiment, steps b, e, and f may be omitted. In particular, it may not be necessary to image the identification pattern in the absence of any analyte. Conversely, it may only be necessary to perform step d, i.e., imaging at least a portion of the identified pattern to obtain image data, digitizing the image data, and determining the Fourier transform image data as a function of one or both spatial frequencies and / or spatial wave vector coordinates, corresponding to page 6 / 36 of the specification 12 CN 121969891 A. The Fourier transform image data can then be analyzed to thereby quantify the quality modulation generated by the immobilized analyte. For example, one or more peaks can be detected in the Fourier transform image data, the amplitude of which indicates the quality modulation. For peak detection, the characteristics of the identified pattern can be used.
[0027] The present invention also relates to a method for screening a biofluid sample for an analyte, preferably a single analyte or a mixture of analytes associated with a protein disease, the method comprising the steps of: a. providing a sensor chip comprising an identification pattern extending in a two-dimensional plane and having first and second pattern elements (particularly ridges and grooves) arranged alternately thereon, at least one of the first and second pattern elements being functionalized with molecular recognition elements for binding the analyte, the identification pattern having a characteristic spatial spectrum in the plane; b. providing a sensing device, the sensing device being or including an imaging microscopy device configured to detect a measurement signal indicating the identification pattern; c. providing a biofluid sample to the sensor chip such that at least a portion of the analyte is fixed at at least some of the molecular recognition elements, thereby modifying the measurement signal; d. imaging at least a portion of the identification pattern to obtain a spatial measurement signal as one or two of the molecular recognition elements in the plane.Image data as a function of coordinates, digitizing the image data, and determining Fourier transform image data as a function of one or two corresponding spatial frequencies and / or spatial wave vector coordinates, e. determining improved Fourier transform image data by filtering the Fourier transform image data using the characteristic spatial spectrum of the identification pattern, and f. re-transforming the improved Fourier transform image data into direct space to obtain improved image data, and thereby quantifying the quality modulation contrast generated by the immobilized analyte.
[0028] In one embodiment, the pattern element includes multiple types of pattern elements, such as a first type of first pattern element and a second type of second pattern element. The first pattern element may be a ridge of the identification grating, and the second pattern element may be a groove of the identification grating. At least one of the types of pattern elements may be functionalized with a molecular recognition element.
[0029] In one embodiment, the identification pattern includes multiple different types of pattern elements. Each type of pattern element has different spatial periodicity and / or symmetry. Therefore, the identification pattern has multiple corresponding characteristic spatial spectra in the plane. In such embodiments, the multiple different types of pattern elements may each be functionalized with different types of molecular recognition elements. Therefore, different types of analytes with similar or different masses can be efficiently identified.
[0030] Alternatively or additionally, Fourier transform image data can be determined by filtering the Fourier transform image data within a spatial frequency filtering range outside the characteristic spatial spectrum of the identification pattern and / or by amplifying the Fourier transform image data within a spatial frequency amplification range within the characteristic spatial spectrum of the identification pattern.
[0031] By immobilizing the analyte, providing the biofluid sample to the sensor chip induces a frequency or periodicity distribution of the identification pattern. This causes a modification of the measurement signal.
[0032] The biofluid sample can be provided to the sensor chip by a third party at a remote location or in an environment separate from at least some of the methods disclosed herein. For example, a user can receive the sensor chip, apply the biofluid sample, and then provide the sensor chip together with the applied biofluid sample for analysis.
[0033] In one embodiment, the method can be used for drug discovery.
[0034] The method and the corresponding apparatus have several advantages. Most importantly, they allow for improved Fourier mass spectrometry analysis. The modulation affinity of the pattern can distinguish selectivity from other binding events because the mass captured by the pattern is modulated accordingly, as described on page 7 / 36 of the specification, CN 121969891 A. The physical sensitivity of this method is theoretically limited by the amplitude of the mass modulation, and because aggregated matter has a greater mass than monomeric forms, even if they are scarce, and even if the recognition element has a strong affinity for monomeric forms...Affinity can also be detected in biological fluids. Since the method and apparatus can operate in a label-free manner, the sensitivity of the method is not limited by the number of exposed epitopes; any randomly or peripherally captured biological material, even if only co-aggregated with the target material, will contribute to quality-related imaging contrast; and in the case of white light interferometry (WLI) with secondary amplification intensity. In step e, improved Fourier transform image data is obtained by Fourier filtering, such that a relative enhancement of the Fourier transform image data is achieved in at least a portion of the characteristic spatial spectrum of the identified pattern. Thus, Fourier filtering in the spatial frequency space allows for the establishment of digital spatial locking amplification by enhancing the image data in the spatial spectrum predetermined by the regularity features of the identified pattern.
[0035] In particular, Fourier amplitude spectrum analysis can be used to determine the size, density, or mass of the analyte.
[0036] In one embodiment, two sets of image data are recorded. First image data of the identified pattern is recorded in the absence of any analyte. Second image data is recorded when the analyte has been applied to the identified pattern. By comparing the first image data and the second image data, it is possible to separate the signal generated by the analyte combined with the recognition pattern, in particular to obtain improved image data for quantifying quality modulation contrast. This comparison can occur in real (direct) space or in Fourier space.
[0037] For example, the first image data can be subtracted from the second image data, and the resulting difference indicates the analyte combined with the recognition pattern. Subtraction can occur in real space or in Fourier space.
[0038] If the comparison is made in Fourier space, the result can be transformed back to real space to obtain improved (real space) image data from which quality modulation contrast can be quantified. Furthermore, if the comparison is made in Fourier space, one-dimensional or two-dimensional Fourier spectra can be truncated, in particular by filtering out one or more portions of the Fourier spectrum that do not correspond to the characteristic spatial spectrum of the recognition pattern. Specifically, one or two peaks in the Fourier spectrum can be separated, which correspond to the spatial spectrum of the recognition pattern in the direction of the one or two pattern vectors. The pattern vector direction corresponds to the lattice vector of the recognition pattern.
[0039] In one embodiment, the first image data is predefined and can be generated and pre-stored by a computer. The first image data is associated with an identification pattern. In other words, corresponding idealized or synthetic first image data generated using a model of the identification pattern can be used. The generation of the first image data may further depend on the type or model of the imaging microscopy apparatus used to generate the second image data. Therefore, only the second image data actually needs to be recorded by the imaging microscopy apparatus.
[0040] The identification pattern may be in the form of an identification grating or a functionalized first pattern element and an unfunctionalized first pattern element.Any other spatially repeating arrangement of a second pattern element, either functionalized or functionalized in a different way. Recognition patterns typically exhibit some degree of spatial periodicity and symmetry.
[0041] The recognition pattern may be formed at least partially by periodically repeating DNA origami nanostructures. The DNA origami structure is a two-dimensional structure extending across at least a portion of the surface of the sensor chip. The DNA origami structure includes scaffold chains and staple chains. The DNA origami structure provides the pattern element.
[0042] Individual DNA origami structures do not need to be coherently assembled adjacent to each other. Integration of similar or different DNA origami nanostructures is possible.
[0043] The pattern element may be functionalized with a molecular recognition element. The pattern element may form part of or be attached to the staple chain. The molecular recognition element may be connected to the staple chain via a connector element.
[0044] In one embodiment, the DNA origami structure includes at least two different types of molecular recognition elements. Two different types of molecular recognition elements may have different spatial periodicity and / or symmetry. Different types of molecular recognition elements can be attached to the same type of staple chain using the same connector element, or they can be attached to different types of staple chains using the same or different connector elements.
[0045] In one example, a first set of staple chains can form a first pattern element and attach a first type of molecular recognition element thereto, forming the first type of molecular recognition element or otherwise providing the first type of molecular recognition element. Optionally, a second set of staple chains can form a second pattern element and attach a second type of molecular recognition element thereto, forming the second type of molecular recognition element or otherwise providing the second type of molecular recognition element.
[0046] In one embodiment, the unit cell of the DNA origami structure has a plurality of symmetrically independent recognition elements, and their frequencies and orientations relative to each other are not multiples of each other.
[0047] In one embodiment, multiple different DNA origami nanopatterns or an integration of the multiple different DNA origami nanopatterns exist on the same sensor chip. The digital image data of the sensor chip can then be analyzed, wherein image data of each DNA origami structure is added to other corresponding structures to improve the signal-to-noise ratio. This may require identifying DNA origami structures, rotations, stacking, averaging, etc.
[0048] In one embodiment, the DNA origami nanopattern has a reference marker that breaks the symmetry of the pattern, so the relative position and / or orientation of each unit cell can be defined and easily detected in the image data.
[0049] In one embodiment, the DNA origami nanopattern has a fixed reference marker, which...The material is a solid nanoparticle that provides orders of magnitude greater scattering contrast. Benchmark markers are used to find and select meaningful regions in electron micrograph image data, even if the DNA origami pattern is not immediately visible due to being hidden by randomly deposited material. The selected regions can be used for multivariate statistical analysis, such as that established when 3D reconstructing a single protein using high-resolution cryogenic transmission electron microscopy.
[0050] Periodic functionalized DNA origami structures on glass slides are known, which are region-selectively decorated or functionalized with many different trapping elements or molecular recognition elements, and each element can have a spatial accuracy of less than 1 nm. These highly coherent nanostructures can be further equipped with a series of different molecular recognition elements, thereby enabling periodic and multiplexed recognition patterns with very high spatial frequencies to be realized in a relatively small sensor area.
[0051] Multiple DNA origami structures can be randomly deposited on a sensor chip and analyzed simultaneously and independently of each other using the methods described herein. In particular, imaging microscopy devices such as atomic force microscopy, X-ray microscopy, or electron microscopy can be used to detect intensity and / or mass modulation resulting from differential analyte binding at different locations of the recognition pattern, especially oligonucleotides and small molecule binders.
[0052] Binding events associated with the recognition pattern can be distinguished from random binding events, especially if image data is analyzed in Fourier space. Random binding events are pattern-independent and expected at low spatial frequencies because they behave independently of each other here and there.
[0053] The recognition patterns of the aforementioned type can be incubated with a biofluid sample derived from the patient and can be washed after a dedicated incubation time. Loosely or non-specifically bound bio-organic material may be washed away, while analytes tightly bound to the recognition pattern may persist and remain attached or adhered. Such incubation-washing experiments are easy to perform and can be implemented anywhere, such as in the patient's or user's home. The incubated sensor can be dried and fixed and then easily stored or sent using the devices or methods described herein for later analysis. Since the analytical readout is only related to the mass modulation aligned with the recognition pattern, the biomaterial on the sensor exhibits less denaturation during storage and transport, as the mass remains constant upon drying.
[0054] The affinity recognition pattern of the type mentioned above can be analyzed using infrared microscopy, and the adsorption intensity profile periodically aligned with the pattern can be used to distinguish between selective and non-specific intensity signals, thus requiring a smaller sample volume compared to existing technologies. For example, a much lower sample volume or mass can be used than in existing technologies, depending on the specific characteristics.The type of analysis. For example, with the highest sensitivity and using WLI, an analyte in a region of two-digit picograms per square millimeter can be detected. Sub-picograms per square millimeter can be used for AFM, which is equivalent to atacers per square micrometer and single atoms per square nanometer.
[0055] Compared to confocal coherent molecular holography using the evanescent field effect, the identification pattern can be read out in a simplified manner and with high throughput. The detection device can include optical profiling, such as low-coherence white light interferometry (WLI), confocal scanning microscopy, IR and Raman microscopy, phase contrast microscopy, scanning probe microscopy and / or electron microscopy. Background speckle patterns are avoided and coherent light diffraction is not required, which simplifies the arrangement of the sensor chip for readout by the sensing device, and the overall spatial locking principle has a wider applicability to large objects. In particular, the wavelength of the coherent light and the spatial wavelength of the identification pattern (or correspondingly, the spatial carrier frequency) do not need to be matched to each other. Therefore, the wavelength of the identification pattern can be scaled over a wide range of scalability, depending on the need or ease of generating and / or functionalizing the identification pattern, and / or on at least partially avoiding the wavelengths of typical spatial noise components. Through digital spatial locking amplification, the sensing device suppresses ambient noise and filters out non-specific binding events. Thus, mass modulation contrast and analyte quantization are achieved in a simplified manner and with an increased signal-to-noise ratio.
[0056] The size, symmetry, and alignment of the identification pattern are less constrained and can be adapted for specific purposes. Known techniques in DNA nanotechnology can be used to construct coherent and multiplexed nanopatterns. The high spatial frequencies of these nanopatterns allow the digital locking amplification principle to be applied at the single-molecule level, resulting in a significant reduction in sensor surface area. Sensor surfaces decorated or functionalized with many similar or even different DNA origami nanostructures are expected to have higher sensitivity than similarly sized sensor regions with microstructures, and even rare analytes can become detectable.
[0057] In addition to the real-time detection of analytes related to protein diseases, the broader applicability of this method enables new experimental spaces. Many submillimeter-sized sensor chips can be analyzed using a sample positioning platform, typically part of any commercial optical profilometer and many types of microscopes (AFM, EM, etc.). The chip can be incubated with a probe liquid, washed, sent, and later analyzed in its dried form, maintaining constant mass modulation. Because the periodicity of the pattern does not require matching the wavelength of the detection principle (such as the wavelength of a laser), recognition patterns can be designed to match analyses at available magnifications and working distances. Therefore, detection principles can be performed within a well plate, enabling interaction analysis of reporter molecules, biomarker monitoring in drug discovery, and many other applications.(At high throughput). Unlike other methods, the method according to the invention is applicable not only at the molecular or level, but also reliably for larger aggregates, such as aggregates of cells and cellular components, with a size of at least 10x or even 50x that of a single human cell. Furthermore, the method is not limited to the wavelength used.
[0058] Another advantage is that one-dimensional or two-dimensional images of the identification pattern can be acquired simultaneously using a one-dimensional or two-dimensional imaging detector (e.g., an optical detector array in white light interferometry) or by a one-dimensional or two-dimensional scanning procedure across the identification pattern (e.g., in atomic force microscopy or confocal microscopy). Furthermore, in dynamic imaging applications, one-dimensional or two-dimensional films of the identification pattern can be acquired by repeated image acquisition using a one-dimensional or two-dimensional imaging detector (e.g., an optical detector array in white light interferometry); and / or by repeated image acquisition using a one-dimensional or two-dimensional scanning procedure across the identification pattern (e.g., in atomic force microscopy or confocal microscopy). One-dimensional or preferably two-dimensional image acquisition also has the advantage of being able to read out multiple recognition patterns (10 / 36 pages, 16 CN 121969891 A), and their Fourier mass distributions can be analyzed in parallel and preferably simultaneously. Therefore, the method according to the invention can be performed in high throughput. In particular, the method according to the invention can be performed in a high-throughput and simple-to-operate manner because the results can be easily read out and interpreted, for example, by comparison with standard analyte measurements.
[0059] The method and apparatus according to the invention preferably represent a method for measuring the mass of an analyte, particularly aggregates, in the presence of a monomer, especially in conjunction with a targeted epitope; even if the analyte concentration is at the affinity limit of the molecular recognition element. The method and apparatus allow the detection or monitoring of molecular interactions, such as the binding of an analyte in a biofluid sample containing a large number and variety of background binding couples, which may interfere with the molecular interactions of the analyte in wash-free and real-time formats, i.e., allowing wash-free and real-time immunoassays. This is because the non-specific binding of background binding couples is diluted over a large spectral range in Fourier space and is therefore undetectable by the sensing method and apparatus.
[0060] The biofluid sample can typically be a sample already obtained from the subject. The biofluid is preferably any solution or suspension derived from human or animal bodies (i.e., bodily fluids, such as, but not limited to, blood, serum, plasma, cerebrospinal fluid, interstitial fluid, saliva, tears, urine) or derived from in vitro cells or biochemical systems. However, it is clear that the method according to the invention is generally performed in vitro. In some embodiments, the biofluid sample has been obtained from a subject who has not yet been diagnosed with a protein disease (e.g., a human subject). The biofluid sample may also include samples derived from human or animal bodies or derived from in vitro cell culture systems (i.e.,Biofluid samples are all biofluids and biochemically processed forms of tissues, cells, or excretions (tissue or cell extracts or homogenates, fecal samples). Biofluid samples may also include intact cellular or subcellular structures (e.g., but not limited to, nuclei, lysosomes, exosomes, vesicles, nucleic acids containing molecules such as DNA and RNA, or lipid aggregates) isolated from or derived from in vitro cell culture systems from human or animal bodies. Biofluid samples typically contain analytes associated with protein diseases. Such analytes expose portions, particularly molecular portions, on their surfaces that are known to play a role in protein diseases. For example, it can be a portion present in some form or three-dimensional structure, or a portion present at different levels in biofluid samples obtained from patients with protein diseases compared to healthy subjects or patients with different conditions. Biofluids are preferably any aqueous fluid derived from human or animal bodies (i.e., bodily fluids, such as but not limited to blood, serum, plasma, cerebrospinal fluid, interstitial fluid, saliva, tears, urine) or derived from in vitro cells or biochemical systems.
[0061] As mentioned above, a plurality of first molecular recognition elements are configured to bind an analyte associated with a protein disease. In particular, only the first molecular recognition element of the first molecular recognition element and the second molecular recognition element is configured to bind an analyte associated with a protein disease. Typically, the first molecular recognition element and the final second molecular recognition element contain one or more binding sites or affinity sites.
[0062] In some embodiments, step b. is performed, i.e., providing a biofluid sample to the sensor chip or sensing device such that the biofluid sample is provided along the flow direction. That is, the biofluid sample is provided such that it flows over a first surface of the sensor chip and / or then flows to other recognition patterns. This can be achieved, for example, by a fluid system of the sensing device. Such a fluid system may, for example, include one or more channels, such as microchannels.
[0063] In some embodiments, the first molecular recognition element and the final second molecular recognition element may be an antibody, particularly a nanobody, a protein, a peptide, an engineered sequence of a natural L- or artificial D-type amino acid, a peptide polymer derived from an amino acid-like molecule, or a single-chain or double-chain sense or antisense oligonucleotide sequence or structure, or a small molecule. In a particular embodiment, the first molecular recognition element and the final second molecular recognition element are antibodies. Alternatively, the first molecular recognition element and the final second molecular recognition element may be chemical and / or physical binders configured to bind an analyte associated with a protein pathology in any chemical bonding or physical attraction event further referred to below as “binding”.
[0064] The methods and apparatus according to the invention allow for the direct measurement of the mass trapped in highly complex biological samples (i.e., any molecular interactions between the molecular recognition element and the analyte) and can largely suppress environmental noise, according to the specification.Page 11 / 36 17 CN 121969891 A Because it employs the principle of digital spatial affinity locking and inherently self-references with the pattern period or spatial frequency or pattern wavelength of the recognition pattern. Therefore, the method according to the invention can detect the quality of analytes associated with proteopathies or the aggregates they form, and can determine the composition or in situ formation of complex aggregates. The aggregates formed can be complex, however, they can be detected as long as they expose at least one binding site that can interact with the first and optionally the second molecular recognition element. This is particularly advantageous for certain analytes associated with proteopathies, as they have been found to recruit additional materials, such as any residual biological material, such as cellular and subcellular components, such as mitochondria, cell membranes, vesicular membranes, nucleic acids, proteins, small molecules, peptides and their poorly soluble digestible fragments, which leads to the growth of highly heterogeneous and complex aggregates.
[0065] In some embodiments, the sensor chip is incubated with a biological fluid for a certain period of time, then washed, sent and analyzed. The optical device is equipped with a micrometer positioning platform and is capable of automatically adjusting the focal point on the surface of the sensor chip. Many identification patterns on a single sensor chip or an array of different sensor chips can be analyzed automatically and at high throughput. This enables the efficient collection and analysis of data from large populations of samples; otherwise, large patient-related databases remain difficult to access.
[0066] In some embodiments, the first molecular identification element and the final second molecular identification element may each contain only one binding site, or they may each contain multiple binding sites, particularly multiple different binding sites. In some embodiments, the first molecular identification element may contain only a single binding site of each first molecular identification element configured to bind an analyte associated with a protein disease, or they may each contain multiple binding sites of each first molecular identification element configured to bind an analyte associated with a protein disease, particularly multiple different binding sites of each first molecular identification element configured to bind an analyte associated with a protein disease.
[0067] In embodiments, the identification pattern is configured such that its characteristic spatial spectrum includes at least one peak region representing the pattern period or equivalent pattern wavelength and / or pattern shape of the identification pattern. Therefore, the identification pattern provides a spatial carrier frequency that allows for the separation of relevant image data associated with the identification pattern from background noise that is largely unrelated to the identification pattern.
[0068] In one embodiment, the identification pattern is implemented as an identification grating.
[0069] In an embodiment, the pattern wavelength of the identification pattern is selected to be shorter than the typical distance between spatial noise components originating from or arbitrarily combined with the identification pattern in a biological fluid sample. Designs with such short wavelengths or equivalents...Such highly periodic or spatially frequency-dependent identification patterns having alternating first and second pattern elements allow for the substantial separation of the noise spectrum from the image data spectrum, which is largely contained at the spatial carrier frequency of the identification pattern, and thus improves the efficiency of filtering the Fourier transform image data in step e.
[0070] In an embodiment, in step e., the improved Fourier transform image data is determined by low-pass filtering, high-pass filtering, or band-pass filtering to discard spatial noise components outside at least one peak region of the characteristic spatial spectrum of the identification pattern.
[0071] In an embodiment, the pattern may have a first pattern element and may further have alternating second pattern elements, the first pattern element being selected from: lines of functionalized sites that are repeatedly offset in the lateral direction; straight lines or curves of functionalized sites that are repeatedly offset in the lateral direction; arrays of dotted functionalized sites; and combinations thereof; the second pattern element being selected from: lines of gap sites; straight lines or curves of gap sites; arrays of dotted gap sites; and combinations thereof.
[0072] In embodiments, the sensor chip can be manufactured by photolithography, spotting, or contact printing, and particularly by reactive immersion lithography (RIL) or DNA origami-based nanostructures. This allows for the acquisition of recognition patterns with scalable spatial resolution and quality, achieving pattern wavelengths in the range of 350 to several micrometers (μm) and / or 5 nm to several micrometers (μm), particularly with coherent linewidths in Fourier space. The recognition pattern can be matched to the resolution and usability of a selected imaging microscopy device.
[0073] In embodiments, when fixed, the analyte modifies the morphology (particularly height or height profile) and / or refractive index of the pattern. Such modifications can be read out by the sensing device.
[0074] In an embodiment, the imaging microscopy device may be selected from: a white light interferometer (WLI), a scanning probe microscope (SPM), particularly an atomic force microscope (AFM) or a scanning tunneling microscope (STM), a confocal microscope, particularly a laser scanning confocal microscope (LSCM), and combinations thereof.
[0075] In one embodiment, the imaging microscopy device may include an electron microscope. The electron microscope includes an electron beam configured to analyze the phase difference and spatial mass distribution of an identification pattern, and thereby quantify the mass modulation generated by the immobilized analyte.
[0076] In one embodiment, the imaging microscopy device may include an X-ray diffractometer.
[0077] White light interferometers, atomic force microscopes, and optical imaging devices have the advantage that they can operate in all dimensions.The binding-induced mass or size modulation on the sensor chip is detected, thereby improving flexibility in the design and optimization of such experiments. Furthermore, digital images can be recorded on a periodic arrangement of patterned elements that can be analyzed in Fourier space. One advantage of this technique over conventional focal spot molecular holography is that the periodicity of the sensor chip is scalable, and further, the grating structure can be multifunctional.
[0078] In one embodiment, a single grating structure can already be multifunctional, meaning that multiple different types of molecular recognition elements exist, which reduces the sensor surface area and allows analysis of smaller sample volumes.
[0079] In an embodiment, the imaging microscopy device is an infrared (IR) or Raman spectrometer, and the space-digital locking principle is applied to image the difference in modulation intensity of absorbed IR light caused by the modulated β-sheet content resulting from identified structured aggregates (aβ, tau, aSYN, etc.) with high β-sheet content.
[0080] In an embodiment, such a combination may be a general imaging step using a first imaging microscopy device (e.g., a white light interferometer (WLI)) according to steps d. to e., for reading out a first region of the sensor chip or identification pattern, and may be a detailed imaging step using a second imaging microscopy device (e.g., an atomic force microscope (AFM)) according to steps d. to e., for reading out a second region of the sensor chip or identification pattern, particularly a subregion of the first region. Such a combination of imaging microscopy devices can allow for a first relatively rapid quantization of the mass modulation contrast generated by one of the immobilized analytes and a second, more detailed and slower quantization of the mass modulation contrast generated by the same or different immobilized analytes. The latter can be used to calibrate the readout of an optical profilometer.
[0081] In an embodiment, a multiplexed sensor chip may be provided, comprising a plurality of identification patterns, preferably arranged at different locations on the sensor chip. Multiple identification patterns may include a specific identification pattern characterized by at least one of the following: specific functionalization of at least one of a first pattern element and a second pattern element for combining one or more specific analytes; selection of a specific identification pattern having a specific spatial spectrum in a plane; specific positioning of the identification pattern on the sensor chip; specific arrangement of the identification pattern on the sensor chip, such as a rectangular or square array. Here, "specific" means at least partially different, particularly completely different, and distinguishable during readout. Multiple identification patterns can be used to at least partially determine an immune signature from a measurement, as further discussed herein.
[0082] Alternatively or additionally, the multiplexed sensor chip may also include overlapping identification patterns, the overlappingThe identification patterns have sufficiently different characteristic spatial spectra in the plane, particularly different carrier frequencies. This allows for individual readout of overlapping identification patterns by applying a particularly adapted spatial filtering range and / or a particularly adapted spatial frequency amplification range to each overlapping identification pattern in step e. of CN 121969891 A on page 13 / 36 of the specification.
[0083] In an embodiment, the imaging microscope is preferably a dynamic imaging device for generating a one-dimensional or two-dimensional membrane of analyte binding or aggregation behavior as a function of time at the molecular recognition element.
[0084] In an embodiment, the dynamic imaging device can be combined with a sensor chip that provides multiplexing, the multiplexing sensor chip comprising multiple identification patterns arranged at different locations and / or overlapping on the sensor chip, particularly as disclosed herein.
[0085] Hereinafter, embodiments involving multiple identification patterns (particularly arrays of identification patterns) are disclosed, and in particular embodiments relating to their use for determining partial or complete immune signatures.
[0086] In some embodiments, each identification pattern contains a specific first molecular identification element and a second molecular identification element, and can be read out distinctly from each other, for example by a specific location and / or spatial spectrum on the sensor chip, particularly a carrier frequency. Thus, each identification pattern can generate its own modified measurement signal (step c.) and its own image data (steps d.–e.).
[0087] In some embodiments, one or more measured signals are stored in a memory unit after step e., which is part of or controlled by a control unit (including circuitry and / or a processor).
[0088] In some embodiments, a particular identification pattern of the plurality of identification patterns, particularly the first molecular identification element of each particular identification pattern, is different from the first molecular identification elements of at least some or all of the other identification patterns. Such embodiments allow multiplexing. In particular, the first molecular identification element of each of the plurality of identification patterns is different from the first molecular identification elements of each other's identification patterns. In some embodiments, the first molecular identification element of one or a group of identification patterns is unique compared to other identification patterns of the sensing device. In particular, the first molecular identification element of each identification pattern or each group of identification patterns is unique compared to other identification patterns of the sensing device.
[0089] In some embodiments, the identification pattern of the plurality of identification patterns, particularly the second molecular identification element of each identification pattern, is different from the second molecular identification elements of at least some or all of the other identification patterns. Specifically, the second molecular identification element of each of the plurality of identification patterns is different from the second molecular identification elements of each other's identification patterns. In some embodiments, one identification pattern or a group of identification patterns is different from the other identification patterns of the sensing device.The second molecular recognition element is unique. In particular, the second molecular recognition element of each recognition pattern or group of recognition patterns is unique compared to other recognition patterns of the sensing device.
[0090] One advantage of providing multiple (i.e., more than one) recognition patterns with different first molecular recognition elements is that it allows for the decomposition of the complexity of the analyte associated with the proteopathy and allows for immune signature. For example, the first recognition pattern may include a first molecular recognition element configured to bind a first binding site of the analyte associated with the proteopathy, while another recognition pattern may be configured to bind a second binding site of the analyte associated with the proteopathy. Alternatively, different first molecular recognition elements bind the analyte associated with the proteopathy with different binding affinities. Since in some embodiments the analyte associated with the proteopathy may be not only a single molecule but also an aggregate of multiple parts, such as cellular components or fragments thereof, proteins, nucleic acids, etc., the use of such multiple recognition patterns can provide detailed information about the analyte. By using different first molecular recognition elements, the complexity of the analyte can be decomposition. Each signal generated at the detector of the sensing device (at a specific detector pixel or pixel array or (partial) imaging region of the detector, respectively) depends on the mass-increasing effect of the molecular interaction between the corresponding first molecular recognition element and the analyte. Therefore, each signal can be used as the quantity or parameter of the analyte in a high-dimensional vector space. By employing multiple recognition patterns with different first molecular recognition elements, an immune signature of the biofluid sample and / or analyte can be generated. This immune signature can then be used to identify or monitor analytes associated with protein diseases and allow conclusions to be drawn regarding the identity, nature, and / or clinical or pathological status of the protein disease in the subject from whom the biofluid sample was obtained.
[0091] In some embodiments, the difference between the first molecular recognition element of a given recognition pattern and the first molecular recognition element of another recognition pattern is characterized in that the first molecular recognition elements, or at least their binding sites, are chemically different from each other.
[0092] Additionally or alternatively, in some embodiments, the difference between the first molecular recognition element of a given recognition pattern and the first molecular recognition element of another recognition pattern is characterized in that they are configured to bind different analytes associated with protein diseases.
[0093] Additionally or alternatively, in some embodiments, the difference between a first molecular recognition element of a given recognition pattern and a first molecular recognition element of another recognition pattern is that they are configured to bind different epitopes of an analyte associated with a protein disease.
[0094] Additionally or alternatively, in some embodiments, the difference between a first molecular recognition element of a given recognition pattern and a first molecular recognition element of another recognition pattern is that they are configured to bind different epitopes of an analyte associated with a protein disease.The difference in the first molecular recognition elements of the recognition patterns is that they are configured to bind to the same analyte or epitope with different binding affinities.
[0095] In some embodiments, at least some or all of the recognition patterns, particularly their first and / or second molecular recognition elements, compete for an analyte associated with the protein disease, and step d is performed to monitor the competition of the modified measurement signal or image data of the recognition patterns for the analyte associated with the protein disease for a predetermined measurement time. In some embodiments, the signal measured within the predetermined measurement time is also considered a time-dependent signal and is included in the immunosignature of the biofluid sample.
[0096] In some embodiments, particularly in embodiments where at least some of the recognition patterns compete for an analyte associated with the protein disease, step c is performed to provide a biofluid sample to the multiple recognition patterns, such that the biofluid sample contacts the recognition patterns one after another. These embodiments can be considered as continuous competitive measurements. In such continuous competitive measurements, at least some or even all of the recognition patterns are fluidly connected to each other. That is, the recognition patterns are not separated from each other by wall structures or the like. In continuous competitive measurements, the biofluid sample can be provided along the flow direction, i.e., it flows in a specific direction and thus sequentially contacts the identification patterns. Preferably, in such embodiments, step d. is performed during and optionally before step c. The biofluid sample can also be provided to multiple identification patterns simultaneously, particularly such that it contacts all identification patterns substantially simultaneously. Preferably, in such embodiments, step d. is performed during and optionally before step c. In a preferred embodiment of such continuous competitive measurements, the sensing device includes identification patterns comprising different first molecular recognition elements and / or different second molecular recognition elements. That is, the first pattern element of a given identification pattern may incorporate a different, preferably unique, first molecular recognition element compared to the first pattern element of another identification pattern incorporated into the sensing device.
[0097] In some embodiments, at least some of the identification patterns are separated from each other, particularly by wall structures. Such wall structures can be configured to prevent the biofluid sample from flowing between the separated identification patterns, particularly during or after step c. Such measurements can be considered parallel measurements. Specifically, the identification pattern can be divided into multiple identification pattern groups, wherein different identification pattern groups are separated from each other, for example, by one or more wall structures. Preferably, each group may contain one or more identification patterns. It is also possible that a first molecular identification element and / or a second molecular identification element are associated with another group of identification patterns.Compared to the other two groups, each group is characterized by different first molecular recognition elements and / or second molecular recognition elements. That is, for example, the first group may include two recognition patterns, each having the same first molecular recognition element. However, the second group may also include two recognition patterns, each having a different first molecular recognition element compared to the two recognition patterns of the first group.
[0098] In some embodiments, the method further includes the step of determining the source of at least one or all of the measurement signal or modified measurement signal measured at the detector. By determining the source of the signal measured at the detector, for example, a specific recognition pattern from which the (modified) measurement signal originates can be identified. Since it is known what kind of first molecular recognition element and / or second molecular recognition element is present at each recognition pattern, further information about the biofluid sample and / or the analyte associated with the protein disease can be obtained.
[0099] In some embodiments, the method further includes the step of determining the parameters of the analyte associated with the protein disease from the modified measurement signal or image data with mass difference dependence and optionally time dependence measured in step d. For example, the determined parameter may be, for example, a single point, such as mass or mass per surface area, or the mass increasing or decreasing over time at one or more identification patterns, particularly at their first molecular identification elements, or the slope or any higher derivative or its mass change increasing or decreasing over time at one or more identification patterns, particularly at their first molecular identification elements.
[0100] Additionally or alternatively, the method further includes the step of determining parameters of aggregates of analytes associated with the proteomics, or co-aggregates containing analytes associated with the proteomics, from measurement signal or image data modified with mass difference dependence and optionally time dependence. Again in this case, the determined parameter may be, for example, a single point, such as mass or mass per surface area, or the mass increasing over time at one or more identification patterns, particularly at their first molecular identification elements, or the slope or any higher derivative or its mass change increasing or decreasing over time at one or more identification patterns, particularly at their first molecular identification elements.
[0101] In one embodiment, the imaging microscopy device is a white light interferometer (WLI) that operates under reflection and includes an imaging detector having a linear or planar pixel array configured to acquire interferometric image data containing phase-sensitive information for determining the height and / or refractive index distribution of the identified pattern and thereby determining the mass modulation generated by the immobilized analyte.
[0102] In one embodiment, the imaging microscopy device is a phase contrast microscope.
[0103] In an embodiment, the imaging microscopy device is a scanning probe microscope, such as an atomic force microscope (AFM), which includes mechanical or other sensors or arrays of such sensors to dissect quality-related property differences along a pattern in real space. AFM height data containing surface morphology variations caused by the identified biological material is analyzed and used to calibrate the optical property modulation.
[0104] In an embodiment, the periodicity and spatial dimension of the identification pattern are optimized to measure the identification process of the identification element at a large field of view and a large working distance.
[0105] In an embodiment, the identification pattern can be scaled and integrated into a perforated plate. The pattern frequency can be optimized so that it can be accessed by the imaging microscopy device from the top and / or from the bottom. The perforated plate includes a plurality of perforated sockets arranged in an array on the plate. The identification pattern can be arranged in the bottom region of each perforation. Furthermore, an optically reflective surface, such as that provided by a mirror (e.g., implemented using a silicon wafer surface), will be arranged above or below the identification pattern. The size and parameters of the identification pattern and the specifications of the imaging microscopy equipment (especially the magnification and working distance) are appropriately matched so that mass modulation events can be observed in high throughput.
[0106] The concentration of the reporting molecule, the expression level of the target protein, and the aggregation rate of bioorganic matter can then be monitored in real time, preferably for simultaneous monitoring of multiple wells. This enables the measurement of extracellular bioorganic matter and chemicals at high throughput. Such methods are of great significance for screening experiments; such as for quantitatively searching for aggregation inhibitors. Specification 16 / 36 pages 22 CN 121969891 A Such setup can also be used for real-time monitoring of organoid farms, or toxins or inflammatory markers.
[0107] In an embodiment, the functionalization is based on: a molecular recognition element, in particular an antibody, providing chemical specificity to bind at least one specific analyte associated with a protein disease, and / or configured to bind a specific epitope of an analyte associated with a protein disease, and / or configured to bind an analyte associated with a protein disease or an epitope of an analyte with specific binding affinity. For example, the determined parameter may be, for example, a single point, such as mass or mass per surface area, or the mass at one or more identification patterns, particularly at the first molecular identification element, increasing or decreasing over time, or the slope or any higher derivative or its mass change at one or more identification patterns, particularly at their first molecular identification elements, increasing or decreasing over time.
[0108] In an embodiment, the first pattern element is configured to bind a first analyte, the second pattern element is configured to bind a second analyte, and the sensing device is configured to quantify the difference between the mass modulation contrast generated by immobilizing the first analyte and the immobilizing the second analyte.
[0109] In an embodiment, the method further includes the steps of: determining parameters of the analyte associated with the protein disease from a quantified mass modulation contrast and optionally time; and / or determining parameters of the following from a quantified mass modulation contrast and optionally time: aggregates of the analyte associated with the protein disease, or co-aggregates containing the analyte associated with the protein disease. Also in this case, the determined parameters may be, for example, a single point, such as mass or mass per surface area, or the mass increasing over time at one or more recognition patterns, particularly at their first molecular recognition elements, or the slope or any higher derivative or its mass change increasing or decreasing over time at one or more recognition patterns, particularly at their first molecular recognition elements.
[0110] For example, it can be observed in real time whether the analyte associated with the protein disease recruits additional material to form aggregates or co-aggregates. Furthermore, the recruitment of such additional material can also be observed in real time. The additional material can be any residual biological material, such as cellular components, mitochondria, cell membranes, nucleic acids, proteins, and fragments thereof.
[0111] In some embodiments, the determined parameters are included in the immune signature formed by the analyte of the biofluid sample and / or the protein disease.
[0112] In an embodiment, the method further includes the steps of: determining the presence of aggregates or co-aggregates from determined parameters, particularly wherein the presence of aggregates or co-aggregates is determined if the determined parameters exceed a predetermined threshold within a predefined incubation time; and preferably, determining the presence of aggregates or co-aggregates includes comparing the determined parameters with reference parameters, such as reference parameters obtained from different patient groups or from healthy subjects, or previous parameters of subjects from whom biofluid samples have been obtained.
[0113] In some embodiments, the determined parameters are compared with a database comprising multiple reference parameters, particularly multiple reference parameters from different patient groups, multiple reference parameters from healthy subjects, and / or previous parameters from subjects from whom biofluid samples have been obtained. For example, the database may include reference parameters for multiple patient groups with different protein diseases (compared to other patient groups in the database). The database may also include multiple patient groups with the same protein disease but at different clinical stages (compared to other patient groups in the database). Such embodiments provide valuable data for physicians to assess the presence, nature, stage, and progression of protein diseases.
[0114] In embodiments, analytes associated with protein diseases include one or more of the following: β-amyloid protein, tau, α-synuclein, prion protein, sarcoma fusion protein, wild-type or mutant polyQ huntingtin protein, ubiquitin, ataxin-3, Optineurin, TAR DNA-binding protein 43, neurofibrillary light chain (NfL), myeloid cellsThe soluble or exfoliated trigger receptor 2 (sTREM2), chitinase-3-like protein 1, glial fibrillary acidic protein, and truncated or other post-translational modified forms of these proteins are expressed. Post-translational modifications may include, but are not limited to, phosphorylation, nitration, ubiquitination, glycosylation and glycation, oxidation and oxidative dityrosine bonding, and methylation. In some embodiments, the analyte associated with the protein pathology may also be an aggregate or co-aggregate comprising one or more of the aforementioned portions (including themselves or their post-translational modified forms) and additional material, such as any residual biological material, such as cellular components, mitochondria, cell membranes, nucleic acids, proteins, and fragments thereof.
[0115] In an embodiment, step d. is performed during the measurement time, and image data is measured as a function of the measurement time to determine aggregation behavior, particularly the aggregation of additional material in the biofluid sample, such as any residual biological material, e.g., cellular components, mitochondria, cell membranes, nucleic acids, proteins, and fragments thereof; or step d. includes single-point measurements at specific time points, particularly steady-state measurements.
[0116] In some embodiments, the signal measured within a predetermined measurement time may be further included in the immunosignature of the biofluid sample and / or the analyte associated with the proteopathic disease. When the signal is measured within the predetermined measurement time, additional insights into the nature of the analyte and the proteopathic disease can be obtained. For example, the behavior of molecular recognition elements, particularly different molecular recognition elements, can be monitored over time when the provided biofluid sample is exposed to changing conditions, such as pH, differentially composed culture media, soluble binding couplers (natural ligands), or synthetic or engineered molecules that act as artificial ligands or interfere with the stability of the analyte, such as aggregate stabilizers or aggregate destabilizers as mentioned herein.
[0117] In some embodiments, changes in each signal are measured during a predetermined measurement time, wherein these changes are achieved by aggregation, particularly by aggregation of additional material in the biological sample, such as any residual biological material, e.g., cellular components, mitochondria, cell membranes, nucleic acids, proteins and fragments thereof, particularly cellular components and / or proteins.
[0118] In some embodiments, step d. includes one or more single-point measurements at a specific time point, particularly steady-state or endpoint measurements. In some embodiments, single-point measurements (signals obtained from single-point measurements, respectively) are included in the immunosignature of the biological fluid sample and / or the analyte associated with the protein disease. It should be understood that single-point measurements, particularly steady-state or endpoint measurements, do not preclude accompanying measurements at the predetermined measurement time. Although in some embodiments, step d. may be...This may include only one or more single-point measurements or only measurements for a predetermined measurement time, but in some embodiments, both measurements may also be included in step d.
[0119] In embodiments, a rinsing step is performed after step c, and particularly before or during step d. The rinsing step may be performed with a rinsing solution.
[0120] Alternatively or additionally, a processing step is performed after step b, which preferably includes the application of a processing agent, such as a detergent selected from: ionic agents, solvents, acids, bases, aggregate stabilizers, aggregate destabilizers, and combinations thereof.
[0121] An aggregate stabilizer is a reagent configured to stabilize aggregates, and an aggregate destabilizer is a reagent configured to destabilize (e.g., deconstruct) aggregates. For example, an aggregate stabilizer or aggregate destabilizer may be a chemical molecule, such as a small molecule (which typically has a molecular mass ≤ 1000 Da) or a large molecule (which typically has a molecular mass > 1000 Da), such as an antibody, Fab fragment, or nanobody. In some embodiments, aggregate stabilizers or destabilizers may be recombinant or synthetic forms of analytes associated with proteopathies, natural ligands, synthetic or engineered molecules that act as artificial ligands or interfere with the stability of aggregate analytes. Such embodiments incorporating the application of aggregate stabilizers or destabilizers are advantageous because early proteopathies may exhibit low levels of rigid and stable aggregates, while later proteopathies or multisystem atrophy may exhibit higher levels of rigid-type aggregates, which have less tendency to decay. Therefore, the application of aggregate stabilizers or destabilizers can provide insights into the stage of the proteopathy. Furthermore, in some embodiments, the measured signal may also be included in the immunosignature of the biofluid sample and / or the analyte associated with the proteopathy. Specification 18 / 36 pages 24 CN 121969891 A
[0122] In some embodiments, step d is performed during the rinsing step and / or during the processing step for a predetermined measurement time. This allows monitoring of changes in the measured signal over time and the effects of the rinsing step and / or the processing step. In some embodiments, such signals measured over time may also be included in the immune signature of the biofluid sample and / or the analyte associated with the protein disease.
[0123] In some embodiments, step d. includes a single-point measurement at a specific time point before the rinsing step and / or the treatment step. In some embodiments, step d. includes a single-point measurement at a specific time point after the rinsing step and / or the treatment step. In some embodiments, such measurements, and the signals obtained from such measurements, may also be included in the immune signature of the biofluid sample and / or the analyte associated with the protein disease.
[0124] In some embodiments, the binder is configured to bind to an analyte associated with a protein disease, particularly to a lysosomal marker, mitochondrial marker, nucleotide, sugar, post-translational modification, or mitochondrial DNA associated with a protein disease. This may be particularly advantageous if the analyte is an aggregate or co-aggregate of other materials, such as any residual biological material, e.g., cellular components, mitochondria, cell membranes, nucleic acids, proteins and fragments thereof, particularly cellular components and / or proteins.
[0125] In an embodiment, after step b, a seed amplification assay is performed by adding a binding reagent sample, particularly a protein sample, to an identification pattern. Performing a seed amplification assay involves adding a binding reagent sample, particularly a protein sample, to one or more identification patterns. It should be understood that the binding reagent sample is typically added after step c. Since the analyte associated with a protein disease present in the biofluid sample acts as a seed to trigger aggregation (e.g., aggregation of other monomeric proteins, particularly recombinant or synthetic forms of monomeric analytes). Furthermore, step d. may include measuring each signal across a predetermined measurement time. Preferably, the protein sample comprises monomeric proteins. Monomeric proteins may act as substrates for co-aggregation in the seed amplification assay. Depending on the presence and nature of the analyte for the protein disease, the added protein sample misfolds and aggregates with the analyte during a predetermined measurement time. Since aggregation leads to an increase in mass, it can be easily measured during step d. In the seed amplification assay, the analyte associated with the protein disease (particularly the analyte forming aggregates) can be, for example, as an in situ seed, which co-aggregates with the recombinant or synthetic form of the analyte associated with the protein disease or other binding reagents provided as a therapeutic agent. In some embodiments, the seed amplification assay may further include the addition of other binding reagents besides the protein sample or as a substitute for the protein sample. Binding reagents that may be included in the binding reagent sample may include, but are not limited to, small molecules (i.e., having a mass ≤ 1000 Da, such as PET tracer-like molecules or amyloid structure binders, peptides or oligonucleotides as described above) or large molecules (i.e., having a mass > 1000 Da, such as antibodies, nanobodies, other peptides).
[0126] In a particular embodiment, multiple recognition patterns are used, each recognition pattern having a different first molecular recognition element, as described herein. In such embodiments, seed amplification assays produce different signals due to different interactions at different recognition patterns. In some embodiments, the measured signal may be included in the immune signature of the biofluid sample and / or the analyte associated with the protein disease. Such immune signatures can be highly specific and therefore unique for a particular analyte of the protein disease and / or for the clinical stage of the patient from whom the biofluid sample has been obtained.
[0127] In an embodiment, the method further includes a secondary characterization step for characterizing the state of an analyte associated with a proteopathic disease or aggregates or co-aggregates formed by an analyte associated with a proteopathic disease. In a preferred embodiment, the secondary characterization step preferably includes ELISA, FT-IR, Raman, or fluorescence spectroscopy.
[0128] The secondary characterization can be performed at any time, particularly during or after step c. The secondary characterization step provides secondary characterization parameters. In some embodiments, the secondary characterization parameters are also included in the immunosignature of the biofluid sample and / or the analyte associated with the proteopathic disease. Specification 19 / 36 pages 25 CN 121969891 A
[0129] In some embodiments, the secondary characterization step is performed directly on a biofluid sample that has been provided to one or more identification patterns to a sensor chip. Thus, in such embodiments, the secondary characterization step is performed directly when the biofluid sample is present on the sensing device.
[0130] In some embodiments, one or more signals measured for each identification pattern during step d. form an immunosignature of the biofluid sample and / or the analyte associated with the proteopathic disease. Optionally, other parameters of the protein disease analyte are also included in the immune signature. For example, as mentioned herein, in some embodiments, parameters of the analyte associated with the protein disease may also be included in the immune signature of the biofluid sample and / or the analyte associated with the protein disease, the parameters of which are determined by the quality dependence and optionally time dependence signals measured in step d, the signals measured during seed amplification assays, the determined source of at least one or all signals measured at the detector, the signals obtained by the application of the therapeutic agent, and / or secondary characterization parameters.
[0131] In some embodiments, the immune signature may be considered as a vector, particularly a time dependence vector, whose trajectory in a high-dimensional vector space is unique for the screened biofluid sample. In this context, the term "high-dimensional" means at least three or more dimensions. Each parameter obtained during step d and / or each signal measured deconvolves the complexity of the biofluid sample. The immune signature may be considered as a unique fingerprint of the screened biofluid sample. Therefore, in some embodiments, multiple immune signatures can be generated over time from biofluid samples obtained from the same subject at predetermined time intervals (e.g., annually or semi-annually), and the immune signatures can be compared with each other or with reference data, as further outlined below. Thus, the immune signature is a direct measure of the pathological state of the subject from whom the biofluid sample originated.
[0132] In some embodiments, the immune signature of the biofluid sample is compared with a database containing immune signatures of multiple samples. In particular, the sample may be a patient sample, an autologous patient sample (i.e., from a currently screened biofluid sample), or a biofluid sample from a patient.The samples are (previously screened samples from patients with biofluid samples) and / or reference samples. In a preferred embodiment, the immune signatures in the database are each associated with a clinical state of the protein disease. Thus, by comparing the immune signatures of screened biofluid samples with the immune signatures contained in the database, the nature and / or clinical state of the protein disease associated with the analyte can be characterized. Furthermore, the progression of the protein disease can be predicted. Pattern recognition analysis can also be performed through such database comparison, during which the immune signatures of screened biofluid samples are analyzed to understand specific patterns that may be found in some of the immune signatures stored in the database. This allows for the detection of the protein disease at a very early stage, particularly before identifiable clinical symptoms appear in subjects from biofluid sample sources.
[0133] The comparison with the database can generally be performed by a computer. The database can be stored, for example, in a memory module, such as included in a control unit, computer, server, hard disk drive, or cloud-based server. The comparison with the database can be performed, for example, by a control unit (including circuitry or a processor). High-dimensional and multimodal data types stored in the relevant database or generated in the above analysis can be further analyzed and / or processed by analytical methods of the type of machine learning and artificial intelligence to identify immune signatures.
[0134] In some embodiments, the first molecular recognition element and the second molecular recognition element of each recognition pattern are configured to interact with the same background binding partner. The background binding partner can be any chemical or biological part that can be bound by the first molecular recognition element and / or the second molecular recognition element. These can be molecules, such as small molecules or proteins, receptors present on cells or cellular components in the sample, or binders having epitopes capable of binding to the first molecular recognition element and / or the second molecular recognition element. Such embodiments are advantageous because the interaction with the background binding partner present in the sample and unrelated to the specific analyte associated with the protein disease is essentially undetectable or substantially undetectable.
[0135] In some embodiments, the first molecular recognition element and the second molecular recognition element have substantially the same affinity KD for the same background binding partner.
[0136] In some embodiments, when the molecular recognition element is an antibody or has an antibody size (150 kDa), the first molecular recognition element binds to the first patterned element at a surface density of 0.1 to 40 fmol / mm², particularly 1 and 4 fmol / mm². For smaller affinity elements, such as nanobody or aptamer of 15 to 50 kDa, the first molecular recognition element binds at a surface density of 1 to 320 fmol / mm², particularly 16 and 64 fmol / mm².A surface density of fmol / mm² is used to bind the first patterned element. Alternatively or additionally, when the molecular recognition element is an antibody or has an antibody size (150 kDa), the second molecular recognition element can bind to the second patterned element at a surface density of 0.1 to 40 fmol / mm², particularly 1 and 4 fmol / mm². For smaller affinity elements, such as nanobodies or aptamers of 15 to 50 kDa, the second molecular recognition element binds to the second patterned element at a surface density of 1 to 320 fmol / mm², particularly 16 and 64 fmol / mm². Such surface densities are particularly advantageous when both the first and final second molecular recognition elements are antibodies, as they avoid interactions between antibodies and further allow for relatively dense occupancy of the patterned element, which improves the measurement sensitivity and affinity of the sensing device.
[0137] In some embodiments, the biofluid sample may be pretreated prior to step c. For example, the biofluid sample may be centrifuged and / or filtered prior to step c.
[0138] In some embodiments, steps c. and d. may be repeated at least once, at least twice, or even more times. Each repetition may be considered a screening cycle.
[0139] Each screening cycle may be different. For example, in one screening cycle, only blank biofluid samples may be screened, thereby providing a blank signal. In another screening cycle, the same biofluid sample providing a seed amplification signal may be seeded as described herein. In another screening cycle, processing steps and / or rinsing steps are performed as described herein in some embodiments that provide processing signals and / or rinsing signals. In another screening cycle, continuous competitive measurements are performed according to some embodiments described herein, providing multiple competitive signals. In a preferred embodiment, in another screening cycle, a first continuous competitive measurement is performed by providing the biofluid sample to an identification pattern in a first flow direction, and in a subsequent screening cycle, a second continuous competitive measurement is performed by providing the biofluid sample to an identification pattern in a second flow direction opposite to the first flow direction. In another screening cycle, parallel measurements are performed according to some embodiments described herein, providing parallel measurement signals. In some embodiments of the method according to the invention, any one, two, more, or all of these screening cycles may be performed.
[0140] In some embodiments, the signals and / or parameters obtained in each screening cycle are included in the immune signature of the biofluid sample and / or analyte (particularly an analyte or mixture of analytes associated with protein diseases).
[0141] In embodiments, the methods and apparatus disclosed herein may be combined with a second or other characterization step (e.g., involving labeling).(Note) combination, for example, by incubating with a labeled binder and reading out the labeled binder signal.
[0142] In some embodiments, after step c, one or more identification patterns may be incubated with a labeled, particularly mass-labeled or fluorescently labeled binder. The mass-labeled binder is preferably a binder having a known, identifiable, and optionally unique mass. In some embodiments, the mass-labeled binder may, for example, comprise nanoparticles. The nanoparticles preferably comprise transition metals or transition metal oxides, such as gold, TiO2, Ta2O5, and silver. If a fluorescently labeled binder is used, in some embodiments, the fluorescence signal may be measured with a fluorescence detector. The fluorescence detector is usually additional and therefore a separate detector. In some embodiments, the detected fluorescence signal is included in the immunosignature of the biofluid sample and / or the analyte associated with the protein disease. In some embodiments, the binder may comprise a predefined binding site, which may be specifically configured to bind to the immobilized analyte associated with the protein disease. Generally, in some embodiments, the predefined binding sites of the binder may be configured such that they do not bind to the first molecular recognition element (page 21 / 36, CN 121969891 A) and / or the second molecular recognition element, meaning that the target substance is different.
[0143] In some embodiments, signals measured during or after incubation of one or more recognition patterns with a labeled, particularly mass-labeled or fluorescently labeled binder may also be included in the immunosignature of biofluid samples and / or analytes of protein diseases.
[0144] In another aspect, the present invention relates to an apparatus for screening a biological fluid sample for an analyte, particularly an apparatus for performing the method according to any one of the preceding claims, the apparatus comprising: a. a sensor chip including an identification pattern extending in a two-dimensional plane and having first pattern elements and second pattern elements (particularly ridges and grooves) arranged alternately thereon, at least one of the first and second pattern elements being functionalized by molecular recognition elements for binding the analyte, the pattern having a characteristic spatial spectrum in the plane; b. a sensing device being or including an imaging microscopy device configured to detect a measurement signal indicating the identification pattern; c. a sensing device including a sampling unit for providing a biological fluid sample to the sensor chip such that at least a portion of the analyte is fixed at at least some of the molecular recognition elements, thereby modifying the measurement signal; d. a sensing device including: an imaging unit for imaging at least a portion of the identification pattern to obtain image data as a function of one or two spatial measurement coordinates in the plane; and a processor for processing...The device is configured to digitize image data and is configured to determine Fourier transform image data as a function of one or two corresponding spatial frequency coordinates, e. a processor configured to improve Fourier transform image data by filtering the Fourier transform image data using the characteristic spatial spectrum of the identification pattern, and f. a processor configured to re-transform the improved Fourier transform image data into direct space to obtain improved image data, and thereby quantify the quality modulation contrast generated by the immobilized analyte.
[0145] In an embodiment, the processor is configured to bandpass filter the Fourier transform image data in a selected region, particularly in a narrow spatial frequency range, wherein the pattern of the identification pattern has characteristic spatial frequency peaks representing the pattern period and / or pattern shape of the identification pattern.
[0146] In an embodiment, on the sensor chip, the pattern wavelength of at least one identification pattern is selected to be shorter than the typical distance between spatial noise components originating from or arbitrarily combined with the identification pattern in the biological fluid sample.
[0147] In an embodiment, the identification pattern may have a first pattern element and may further have alternating second pattern elements, the first pattern element being selected from: lines of functionalized sites that are repeatedly offset in the lateral direction; straight lines or curves of functionalized sites that are repeatedly offset in the lateral direction; an array of dotted functionalized sites; and combinations thereof; the second pattern element being selected from: lines of gap sites; straight lines or curves of gap sites; an array of dotted gap sites; and combinations thereof.
[0148] In an embodiment, the sensor chip is multiplexed to include a plurality of identification patterns, the plurality of identification patterns preferably being arranged at different locations on the sensor chip, and in particular, a particular identification pattern is characterized by at least one of the following: specific functionalization of at least one first pattern element or second pattern element for combining one or more specific analytes; a specific feature spatial spectrum in a plane; a specific positioning of the identification pattern on the sensor chip; a specific arrangement of the identification pattern on the sensor chip, for example, in a rectangular or square array.
[0149] In an embodiment, the imaging microscopy device is a white light interferometer (WLI) that operates under reflection and includes an optical imaging detector having a linear or planar pixel array configured to acquire interferometric image data containing phase-sensitive information, for determining the height (i.e., height profile or morphology) and / or refractive index distribution of the identification pattern and thereby determining the mass modulation generated by the immobilized analyte.
[0150] In an embodiment, the imaging microscopy device is a scanning atomic force microscope (AFM) that includes a cantilever or array of cantilever arms configured to scan across a plane to obtain AFM data.AFM image data of feature information is used to determine the atomic or molecular height profile of the pattern and thereby determine the mass modulation generated by the immobilized analyte.
[0151] Throughout this application, the reference to steps by the letters a., b., c., d., etc., does not imply a specific order of steps, but these letters are used as reference letters to identify specific steps of the claimed method. Although it is possible that the method is performed stepwise from step a. to step f., the claimed invention also includes performing the steps in a different order or performing at least some of the steps simultaneously. As an example, the invention also includes step a. (i.e., providing the sensor chip) which may be performed before, during, or after step b. (i.e., providing the sensing device).
[0152] Throughout this application, the term "bonding" or "immobilization" should be understood broadly. It may refer to any chemical bonding or physical attraction event, particularly at the molecular level, such as, but not limited to, one or more of covalent bonding, hydrogen bonding, ionic bonding, van der Waals forces, hydrophobic effects, and phase separation. Similarly, molecular interactions of the first or second molecular recognition element, as used herein, typically include chemical bonding or physical attraction events between the corresponding molecular recognition element and its interacting partner (such as an analyte associated with a protein disease or a background binding partner). In particular, binding or immobilization can occur sufficiently close to or near the molecular recognition element.
[0153] It should generally be understood that a biofluid sample may contain a single analyte associated with a protein disease or multiple analytes associated with a protein disease. In the latter case, the method may be performed on only one, a portion, or all of the protein disease-associated analytes present in the biofluid sample.
[0154] It should generally be understood that the general sensitivity of the spatial-digital locking principle is based on the affinity selectivity differences of the recognition elements employed within a pattern. Therefore, this principle can be used to optimize molecules and their binding in complex biofluids for the purposes of optimizing molecular binding properties and distinguishing selective recognition events from background binding. This principle has applications in drug discovery, monitoring processes, and diagnostics.
[0155] In addition to the method and sensing device, this disclosure also relates to a sensor chip including an identification grating comprising a DNA origami structure functionalized with molecular recognition elements for binding an analyte, the molecular recognition elements forming a substantially periodic pattern.
[0156] More specifically, the identification pattern extends in a two-dimensional plane and pattern elements are arranged thereon. The pattern elements are arranged periodically to form the identification pattern. At least some of the pattern elements are functionalized with molecular recognition elements for binding an analyte. The sensor chip is characterized in that the identification pattern is at least partially composed of periodically repeating DNA comprising scaffold chains and staple chains.Origami structure is formed. DNA origami structure provides pattern elements. Molecular recognition elements are connected to staple chains via connector elements.
[0157] Molecular recognition elements are as described in this disclosure.
[0158] DNA origami structure may include two or more different types of molecular recognition elements. The two or more different types of molecular recognition elements may have different spatial periodicities. In other words, the first type of molecular recognition element forms a pattern different from the pattern formed by the second type, the difference being that the two patterns have different periodicities. In other words, the unit cells of the two patterns do not overlap because the unit cells do not have the same unit cell vectors that define them. As a result, the unit cells of the two patterns may have the same shape but different orientations relative to each other, or the result is that the unit cells have different shapes. Specification 23 / 36 pages 29 CN 121969891 A
[0159] In one embodiment, the spatial periodicity (in particular, one or more unit cell vectors defining the pattern formed by the first type of molecular recognition element) does not have a common factor with the unit cell vectors defining the pattern formed by the second type of molecular recognition element. The same applies to a third type of molecular recognition element, which, if present, will have a cell vector that does not share a common factor with either the first or second type of cell vector. This ensures that the main peaks do not overlap in Fourier space and makes it possible to distinguish signals from each type of molecular recognition element.
[0160] The sensor chip may include multiple recognition patterns implemented as DNA origami (nanostructures). The DNA origami nanostructures may be grouped into multiple groups, each with different properties, and in particular, they include different molecular recognition elements. For example, a first DNA origami structure may include only a first type of molecular recognition element, while a second DNA origami structure may include only a second type of molecular recognition element. Thus, a multiplexed sensor chip is realized.
[0161] In one embodiment, the DNA origami structure includes two or more different types of molecular recognition elements, each molecular recognition element forming a pattern having a cell (defined by a cell vector) that is different from and distinct from one or more other patterns of the molecular recognition element.
[0162] In one embodiment, the cell vectors are not multiples of each other in any dimension. In other words, the unit cell vectors do not have any common factors other than 1. This has the advantage that the principal components are distinct in the Fourier spectrum, thus allowing at least some peaks in the Fourier spectrum to be assigned to specific types of molecular recognition elements, and also allowing each molecular recognition element to have at least one peak in the Fourier spectrum that is not shared with another molecular recognition element.
[0163] In one embodiment, the recognition pattern may not have significant mass modulation. This is also known as a massless recognition pattern.This may be the case with origami structures, where mass modulation can be on the order of just a few nanometers. In such cases, it may not be necessary to compare a sensor chip without any analyte with one with an immobilized analyte.
[0164] The invention described herein will be more fully understood from the detailed description and accompanying drawings given below, which should not be considered as limiting the invention as described in the appended claims. The accompanying drawings illustrate the following: Figure 1 is a schematic block diagram of a screening device for screening biological fluid samples for analytes; Figures 2a and 2b are schematic diagrams of a sensing device as a white light interferometer (WLI) according to an embodiment of the present invention; Figure 2c is a schematic diagram of a sensing device as a confocal microscope according to an embodiment of the present invention; Figure 2d is a schematic diagram of a sensing device as an atomic force microscope (AFM) according to an embodiment of the present invention; Figures 3a, 3b, and 3c show (real-space) image data of the identification pattern obtained using AFM and Fourier transform image data generated using the real-space image data; Figure 4 is a schematic detailed view of an identification pattern according to an embodiment of the present invention; Figure 5a is a schematic detailed view of a cross-section of an identification pattern used in a method according to the present invention for screening analytes associated with proteopathies that form aggregates, and a schematic aggregation curve; Figure 5b is a schematic detailed view of a cross-section of an identification pattern used in a method according to the present invention for screening analytes associated with proteopathies that exist as monomers, and a schematic aggregation curve; Figure 6 Schematic detailed view of a cross section of the identification pattern used in the method according to the invention for use after washing and with an additional quality-labeled binder, and schematic aggregation curve; Specification 24 / 36 pages 30 CN 121969891 A Figure 7 Schematic detailed view of a cross section of the identification pattern used in the method according to the invention, and schematic aggregation curve, wherein a treatment step including the application of a detergent is performed after a predetermined time interval; Figure 8 Schematic detailed view of a cross section of the identification pattern used in the method according to the invention, and schematic aggregation curve, wherein seed amplification assay is performed; Figure 9 Schematic diagram of a method according to an embodiment of the invention, wherein the measured signal forms an immune signature; Figures 10a and 10b Schematic diagram of a portion of a sensing device performing continuous competitive measurements; Figure 11 Schematic diagram of a portion of a sensing device performing parallel measurements; Figure 12 Schematic detailed view of a cross section of the identification pattern used in the method according to the invention, wherein marker proteins expressed on the mitochondrial surface are exposed and used for binding to a first molecular recognition element; Figure 13Figure 14 shows a schematic detailed view of a cross-section of an identification pattern used in the method according to the invention, wherein marker proteins expressed on the surface of lysosomes are exposed and used to bind to a first molecular recognition element; Figure 15 shows a flowchart illustrating a method for screening a biological fluid sample for an analyte; Figure 16 shows a representation of: image data of an identification pattern including vertical lines, together with the same image data revealing the amplitude spectrum of the identification pattern in Fourier space; Figure 17 shows a representation of: image data of the identification pattern of Figure 16 (this time with the analyte present), represented as small dots selectively bound to the space in the identification pattern; together with the Fourier transform of the same image, showing how the amplitude of the peaks in the spectrum changes due to the presence of the analyte; Figure 18 shows Figures 16 and 17. The image data representation of the recognition pattern further includes white, randomly oriented objects, demonstrating that the signal in the Fourier spectrum is robust to random noise that does not selectively bind to either the ridge or the groove; Figure 19 shows a schematic diagram of a recognition pattern including a DNA origami structure, where molecular recognition element “a” is connected to a staple chain via a connector element, and the molecular recognition element forms the pattern; Figure 20 shows a schematic diagram of a larger cross-section of the recognition pattern formed by the DNA origami structure shown in Figure 19, including its Fourier spectrum and the corresponding retranslation of the major Fourier components back to real space; Figure 21 shows a schematic diagram of a recognition pattern including a DNA origami structure, where multiple different types of molecular recognition elements “a”, “b”, “c” are connected to a staple chain, each of the different types of molecular recognition elements forming a recognition pattern with a different spatial frequency; Figure 22 schematically shows the different spatial periodicities of molecular recognition elements “a”, “b”, “c”; and Figure 23 shows an electron microscope image of a sensor chip including multiple recognition patterns, each recognition pattern being a rectangular two-dimensional DNA origami structure. Detailed Description
[0165] FIG1 shows a block diagram schematically illustrating a screening device 1. The screening device includes a sensor chip 3, a sensing device 10, and a control unit 4. The sensing device includes an imaging microscopy apparatus 2. The control unit 4 is connected to the imaging microscopy apparatus 2.
[0166] Optionally, the screening device 1 includes a fluid cell containing a sample to be measured.
[0167] The control unit 4 embodies a programmable device and includes, for example, one or more processors 41, and is described on pages 25 / 36 of the specification 31 CN 121969891 AOne or more memory modules 42 storing program code and data, and a programming software module for controlling the processor 41 and / or other programmable circuits or logic units (such as ASICs (Application-Specific Integrated Circuits) and / or GPUs (Graphics Processing Units)) included in the control module 4. The memory modules 42 include volatile and / or non-volatile storage media, such as random access memory and / or flash memory. The control module 4 is connected to other components and modules of the screening device 1 disclosed herein, particularly the sensing device 10. The connection is wired and / or wireless, and is configured to exchange control signals and / or sensor signals.
[0168] Depending on the embodiment, the control module 4 further includes a communication interface. The communication interface is configured for data communication with one or more external devices. Preferably, the communication interface includes a network communication interface, such as an Ethernet interface, a WLAN interface, and / or a radio network interface, for wireless and / or wired data communication using one or more networks, including, for example, local networks such as LANs (Local Area Networks) and / or the Internet.
[0169] Control module 4 performs one or more steps and / or functions as described herein, for example, according to program code stored in the one or more memory modules 42. Additionally or alternatively, the program code may be stored wholly or partially in one or more auxiliary processing devices (e.g., computers). Those skilled in the art will recognize that at least some of the steps and / or functions described herein, as performed on processor 41 of screening device 1, may be performed on one or more auxiliary processing devices connected to screening device 1 using a communication interface. The auxiliary processing devices may be co-located with or remotely located from screening device 1, for example, on a remote server computer.
[0170] Those skilled in the art will also recognize that at least some of the data associated with the program code (application data) or data associated with a particular analyte and described as being stored in the memory of screening device 1 may be stored on one or more auxiliary storage devices connected to screening device 1 using a communication interface.
[0171] Figures 2a to 2c illustrate three different embodiments of a sensing device 10 implemented as a phase contrast microscope. It should be understood that other types or arrangements of phase contrast microscopes are known and can be used to implement the invention disclosed herein.
[0172] FIG2a schematically illustrates an embodiment of a sensing device 10, which includes, in particular, a white light interferometer (WLI) 100. The WLI 100 is a special type of Michelson interferometer. The WLI 100 is configured to scan the height and / or refractive index of the sensor chip 3 (in particular, the identification pattern 3 on the sensor chip 3).
[0173] The WLI 100 is shown arranged in a camera101, particularly between the CCD camera and the sensor chip 3. Alternating first pattern elements 8 and second pattern elements 9 are indicated by alternating lines. A reflective surface 102, such as a mirror, is arranged on the side opposite the sensor chip 3 and the interferometer 100. The WLI 100 provides an optical measurement signal to the camera 101, which is modified according to an analyte adhered to the surface of the sensor chip 3. In particular, a stripe pattern is formed on the surface of the readout and digitized camera 101, and the stripe pattern is modulated / modified according to the analyte.
[0174] For illustrative purposes, the WLI 100 is depicted, wherein multiple rays extend between the WLI 100 and the sensor chip 3 and also between the WLI 100 and the camera 101.
[0175] As schematically shown in a detailed view of the WLI 100, the WLI 100 includes a tri-color LED 103 configured to emit white light. White light is incident on beamsplitter 104, which deflects a portion of the light toward camera 101 and allows another portion of the light to pass through. This portion of the light passing through beamsplitter 104 is reflected from reference plane 105 (which is reflective), and this reference plane can be adjusted to increase or decrease the distance between reference plane 105 and beamsplitter 104. Again, a portion of the light incident on beamsplitter 104 is reflected from beamsplitter 104 and onto sensor chip 3, where it is reflected from reflective surface 102 and passes through the arm of WLI 100 again. The varying arm length between beamsplitter 104 and reference plane 105 (on one hand) and with reflective surface 102 (on the other hand) causes the intensity of the light incident on camera 101 to vary due to interference. Specification page 26 / 36 32 CN 121969891 A
[0176] Depending on the field of view of WLI 100, WLI 100 can move in x-y coordinates so that the entire sensor chip 3 can be imaged. For each position on the surface of sensor chip 3 (using, for example, Cartesian x-y coordinates), WLI 100 moves reference plane 105 (e.g., moves reference plane 105 back and forth) to determine the location of the maximum and / or minimum intensity of light measured by camera 101. When measuring the maximum light intensity, the position of reference plane 105, for example, indicates the height and / or refractive index of sensor chip 3 at the specific location of sensor chip 3 that WLI 100 is currently measuring. Alternatively and / or additionally, the distance between sensor chip 3 and beam splitter 104 can also be controlled to identify the location of the maximum and / or minimum intensity of light. However, if the field of view is large enough to image the entire sensor chip at once...3. For imaging, such movement is unnecessary.
[0177] WLI 100 can be configured, for example, in conjunction with control unit 4, to scan at least a portion of the surface of sensor chip 3, particularly including at least a portion of the surface of the identification pattern 5, thereby obtaining image data as a function of one, two, or more measurement coordinates in the x-y plane.
[0178] The image data is then provided to control unit 4. Control unit 4 then performs a Fourier transform on the image data to determine Fourier transform image data as a function of one or two spatial frequency coordinates corresponding to the one or two measurement coordinates.
[0179] FIG2b shows a schematic diagram of an embodiment of a sensing device 10 including an imaging microscopy apparatus 2, which includes or is particularly implemented as a phase-shifting white light interferometer (PSWLI) or a vertical scanning white light interferometer 110 (VSWLI). VSWLI can also be called a Mirau interferometer, which operates on the same principle as a Michelson interferometer, except for the physical arrangement of the reference arms. In the Mirau interferometer, the reference arm is positioned within the microscope objective assembly.
[0180] Similar to the WLI 100 described with reference to FIG2a, the PS- / VSWLI 110 is arranged between the camera 111 and the sensor chip 3, wherein the sensor chip 3 includes the identification pattern 5. For illustrative purposes, light rays extending from the PS- / VSWLI 110 to the sensor chip 3 and from the PS- / VSWLI 110 to the camera 110 at multiple locations along the x-axis are shown. However, the PS- / VSWLI 110 is configured to measure only a single location in the plane (i.e., in the x-y plane) at a time, and is configured to scan across the plane (i.e., across the x-y plane), thus measuring multiple x-y locations sequentially.
[0181] The PS- / VSWLI 110 includes 3-color LEDs 113. Downstream of the three-color LED 113, an aperture stop 114 is arranged. Light from the three-color LED 113 is incident on a beam splitter 116, which reflects a portion of the light downwards, through the objective lens housing, and through a reference plane 118 and another beam splitter 119, before being reflected onto the sensor chip 3. Behind the sensor chip is a reflective surface 112, specifically an atomically smooth mirror plane. The objective lens housing is mounted on a piezoelectric stage 117, which is configured to move the PS- / VSWLI in the x-y plane, specifically the focal point on the sensor chip 3, to scan the sensor chip 3. The piezoelectric stage 117 can further alter the relationship between the PS- / VSWLI 110 and the sensor chip 3.The distance between them. Beam splitter 119 and reference plane 118 are configured to form a reference beam. The reference beam interferes with the measurement beam incident on sensor surface 3. In particular, the distance between beam splitter 119 and reference plane 118 can be configured to be the same as the distance between beam splitter 119 and the surface of recognition pattern 5, such that constructive interference occurs between the reference beam and the measurement beam, and the light intensity incident on camera 111 is increased.
[0182] By scanning at least a portion of recognition pattern 5 on sensor chip 3, image data as a function of one, two or more measurement coordinates in the x-y plane is obtained.
[0183] The image data is then provided to control unit 4. Control unit 4 then performs a Fourier transform on the image data to determine the Fourier transform image data as a function of one or two spatial frequency coordinates corresponding to the one or two measurement coordinates. (See page 27 / 36 of CN 121969891 A for more details.)
[0184] The benefits of PSWLI and VSWLI 110 include delivery at medium throughput and speeds determined by the scan rate at a resolution up to 0.1 nm on the vertical (PSWLI) dimension. Mass modulation can be detected with high accuracy, even from large working distances, which have periodicity in the micrometer range and spans over one millimeter. Using phase-shifting interferometry, the topography (i.e., height) can be determined from a series of interferograms. In PSWLI, the maximum z-scan range is matched to the wavelength within the coherence length of white light. VSWLI is suitable for visualizing larger analytes and objects and has slightly lower resolution.
[0185] Figure 2c shows a schematic diagram of a sensing device 10 including an imaging microscopy apparatus 2, which includes or is specifically implemented as a confocal microscope 120.
[0186] The confocal microscope 120 is arranged between the camera 121 and the sensor chip 3 in a manner similar to that of the WLI 100 and VSWLI 110 described above with reference to Figures 2a and 2b. The confocal microscope 120 includes a laser source 123. Alternatively, one or more monochromatic LEDs and / or white light sources may also be used (e.g., implemented using 3-color LEDs).
[0187] A downstream beam splitter 125 is arranged to direct a portion of the laser onto the sensor chip 3. This portion of the laser is directed by a lens system 126 arranged in the objective housing 128, wherein the lens system 126 is configured to focus the laser onto the surface of the sensor chip 3, particularly onto the identification pattern 5. The vertical (height) position of the focal point can be controlled by adjusting the lens system 126 in the vertical direction.The objective housing 128 is adjusted separately, particularly using a z-scanner 127 attached to the objective housing 128, which can be implemented using a piezoelectric stack. Specifically, the z-scanner 127 is configured to focus the laser at a height taking into account any immobilized analyte. The camera 121 can be used to determine whether the focal position coincides with the sensor chip 3 or, in particular, the analyte. Specifically, light reflected from the sensor chip 3 and / or the reflective surface 122 (in particular, an atomically smooth and reflective mirror plane) passes through the lens system 126, through the beam splitter 125, through the pinhole 124, and returns to and is incident on the camera 121, in particular a CCD camera.
[0188] The height position at which the focal point coincides with the identification pattern (in particular the analyte) is recorded at each position in the plane. The confocal microscope 120 scans across at least a portion of the identification pattern 5 and determines the height at each position for generating image data as a function of one, two, or more measurement coordinates in the x-y plane.
[0189] The image data is then provided to the control unit 4. The control unit 4 then performs a Fourier transform on the image data to determine the Fourier transform image data as a function of one or two spatial frequency coordinates corresponding to the one or two measurement coordinates.
[0190] The advantage of the confocal microscope 120 is that it can deliver a vertical resolution of up to 1 nm. However, the lateral size is limited by diffraction. The throughput and dynamic range are also lower. The confocal microscope 120 is particularly advantageous once the size or diameter of the analyte has a size corresponding to the wavelength of the laser source 123.
[0191] FIG2d shows a schematic diagram of an embodiment in which the sensing device 10 includes an imaging microscopy device 2, which includes or is implemented as an atomic force microscope (AFM) 130. The AFM 130 includes a cantilever 131 under which a tip 132 is arranged. A piezoelectric stage 135 is configured to scan the surface of sensor chip 3, particularly identifying pattern 5 or a portion thereof, to determine a height profile (e.g., topography) in one or two spatial directions. The height profile is determined by measuring the deflection of arm 131 by reflecting a laser beam onto the top side of cantilever 131. Specifically, laser source 133 is configured to direct a laser beam onto the top side of cantilever 131. The laser beam is reflected from the top side of arm 131 and incident on sensor 134. Sensor 134, which may be implemented as a position-sensitive device (PSD), a photodetector array, a four-quadrant photodiode, etc., is configured to determine the position of the laser beam. The position of the laser beam indicates the deflection of cantilever 131. (Specification 28 / 36 pages 34 CN 121969891 A Using a Feedback Controller)136. Control the piezoelectric stage 135 such that the cantilever 131 of the AFM 130 contacts the identification pattern 5, but without applying a force that may excessively affect the analyte and / or the arm 131.
[0192] The height of the piezoelectric stage 135 and / or the deflection of the laser beam, as recorded by the sensor 134, can be used to determine the height at a specific location in the plane. A height profile in one or two spatial dimensions can be obtained by scanning across the sensor chip.
[0193] The height profile is used to generate image data as a function of one or two measurement coordinates in the x-y plane.
[0194] The image data is then provided to the control unit 4. The control unit 4 then performs a Fourier transform on the image data to determine Fourier transform image data as a function of one or two spatial frequency coordinates corresponding to the one or two measurement coordinates.
[0195] The AFM 130 can operate in one of several modes, including, for example, a tapping mode or a contact mode. For AFM operation in tapping mode, cantilever 131 can be connected to another piezoelectric element configured to drive the cantilever such that it oscillates, for example, at its resonant frequency.
[0196] FIG3 shows exemplary images and data obtained.
[0197] FIG3a shows an example of image data including an AFM height map recorded on a blank recognition pattern 5, which includes an antibody as a first recognition element 8 and short chains of polyethylene glycol (PEG) as a second recognition element 9. The AFM height map is recorded in air in tapping mode. Mass modulation caused by differences in size and decoration of the different recognition elements 8, 9 is visible in parallel stripes that modulate the morphology along the pattern, i.e., along the recognition pattern 5. The morphology modulation (i.e., height profile) is mapped in real space along with the frequency of the pattern and can be used for calibration of optical methods, particularly for calibration of imaging microscopy apparatus described with reference to FIGS. 2a to 2c.
[0198] FIG3b shows an example of Fourier transform image data. The periodic nature of the image data shown in Figure 3a results in two frequency peaks after the Fourier transform. The frequency peaks at the center of Figure 3b can be seen as a series of horizontally spreading points.
[0199] Figure 3c shows a plot of the amplitude (pm) as a function of the frequency (1 / µm) of the Fourier transformed image data. Due to the photolithography process, two carrier frequencies are found at 397 nm and 367 nm, as indicated by the marked peaks in the plot. These two modulations are visible in the frequency (i.e., Fourier) domain and are also related to the amplitude of the morphological modulation. The signal is analyzed independently of the random contributions along the real space image and the spectral spread, respectively. When the two peak frequencies are re-transformed...When in real space, as indicated by two inserted images showing the real space representation of the two peaks respectively, the filtered stripe modulation of the identification pattern is re-obtained.
[0200] Although in some embodiments, the sensing device 10 (each of its sensor chip 3) includes only one identification pattern 5, the sensing device (each of its sensor chip 3) is likely to include multiple such sensing points in the form of multiple identification patterns 5. This is shown, for example, in Figures 10 and 11.
[0201] Figure 4 shows a detailed view of the identification pattern 5. It can be seen that the sensor chip 3 includes multiple first pattern elements 8, in particular ridges 8, and multiple second pattern elements 9. The first pattern elements 8 and the second pattern elements 9 are interleaved with each other, such that the multiple first pattern elements 8 and the second pattern elements 9 are arranged in an alternating manner. All the first pattern elements 8 (which in this embodiment are in the form of curved elongated lines or strips or ridges) and all the second pattern elements (which in this embodiment are also in the form of curved elongated lines or strips or grooves) together form the identification pattern 5. Multiple first molecular recognition elements (not shown, see, for example, FIG. 5a) configured to bind analytes associated with protein diseases are combined with a first pattern element 8. Furthermore, multiple second molecular recognition elements (not shown, see, for example, FIG. 5a) different from the first molecular recognition elements can be combined with a second pattern element 9. Specification 29 / 36 pages 35 CN 121969891 A
[0202] To combine the available photolithography system with white light interferometry, a recognition pattern, or for example, a recognition pattern having a period of 1.8 μm and a square area of 600 x 600 μm², may be suitable.
[0203] In one embodiment, the recognition pattern is not a diffraction grating. Specifically, the recognition pattern does not act as a diffraction lens, particularly for a specific wavelength or wavelength range. For example, the recognition pattern is not a Fresnel zone plate.
[0204] An embodiment of the high-resolution identification pattern 5 produced by photolithography, particularly reactive immersion lithography (RIL), may have the following parameters: minimum feature size of 1 μm; minimum line spacing of 1.5 μm; address grid size of 50 nm; edge roughness of 150 nm (3σ spacing); CD uniformity of 300 nm (3σ spacing); and second layer alignment above 5 x 5 mm² at 500 nm (3σ spacing) and above 50 x 50 mm² at 1000 nm (3σ spacing). Figures 5a and 5b show a comparison of methods performed on analytes associated with proteomics forming aggregates (Figure 6a) and analytes as monomers (Figure 6b). Both figures show the first pattern element of the identification pattern (e.g., identification pattern 5 shown in Figures 4 and 5).Detailed cross-sectional views of 8 and the second pattern element 9 are shown. It can be seen that multiple first molecular recognition elements 10 bind to the first pattern element 8, and multiple different second molecular recognition elements 11 bind to the second pattern element 9. The analyte 13 associated with the proteomics forms aggregates exposing several binding sites represented by a, b, c, d, and e. Generally, as used herein, different letters refer to different binding sites. That is, in this example, the analyte 13 associated with the proteomics has five different types of binding sites a, b, c, d, and e. It can be seen that the first molecular recognition element 10 contains binding site A, while the second molecular recognition element 11 lacks such binding site A. Generally, as used herein, recognition pattern-specific binding sites represented by uppercase letters (such as binding site “A”) are typically configured to bind analyte-specific binding sites represented by the same lowercase letter (such as binding site “a”), but preferably not to bind binding sites represented by another lowercase letter. As can be seen in Figure 5a, after a biofluid sample is provided for sensing and recognizing pattern 5 and thus sensing its first pattern element 8 and second pattern element 9, the analyte 13 associated with the protein disease binds to binding site A of the first molecular recognition element 10 at its binding site a. In the figure below, the signal measured at the detector is shown as a function of time. Because the non-binding background material present in the biofluid sample does not interact with the first molecular recognition element 10 or the second molecular recognition element 11, or because the non-binding background material interacts with the first or second molecular recognition element with substantially equal probability, the obtained signal is essentially self-referential, and it is not necessary to wash away the background material to obtain a reliable measurement signal. It can be seen that the measurement signal obtained from recognizing pattern 5 begins during time interval 1. The binding of the analyte 13 associated with the protein disease occurs during time interval 2, which results in a mass increase that is clearly visible in the obtained time-dependent signal. Since the first molecular recognition elements 10 can be selected such that they are highly selective binders for the binding site a of analyte 13, such measurements can provide detailed information about the nature or clinical picture of the proteopathic disease. Furthermore, since the system depends essentially only on the quality of the binding pair of the molecular recognition element and its interaction, the complexity and heterogeneity of the aggregates formed by analyte 13 are irrelevant. Figure 3b shows the signal obtained if only monomers are detected. Since the measured signal depends on the quality of the interaction with the molecular recognition element 10, aggregates formed by analyte 13 associated with the proteopathic disease have a significantly strong signal.
[0205] (Referring to Figure 5a)Similarly, Figure 6 also illustrates an exemplary screening of analyte 13 associated with protein diseases that forms aggregates. Likewise, as can be seen from the measured signals, the measurement begins during time interval 1. In time interval 2, a biofluid sample, particularly including analyte 13 associated with protein diseases, is added. Subsequently, in time interval 5, a mass-labeled binder 14 is added. For example, such a mass-labeled binder may contain gold nanoparticles as a mass label.
[0206] Furthermore, in this embodiment or any other embodiment as described herein, the mass-labeled binder may contain a predefined binding site that may be specifically configured to bind to the analyte associated with the protein disease. Generally, the predefined binding site may be configured, for example, such that it does not bind to a first molecular recognition element and / or a second molecular recognition element. As can be seen in Figure 6, when a mass-labeled binder is added, the signal increases during time interval 5 because the binder binds to the analyte 13 that has already bound to the first molecular recognition element 10. Such embodiments are advantageous because they can further aid in deconvolution and thus characterize the protein diseases suffered by patients who are the source of the biofluid samples being screened. For example, if a particular type of disease is known to show analytes exposing binding sites b, the increase in mass indicates the presence of such binding sites b and may therefore help to exclude other protein diseases. It should be understood that the mass label has a determined and known mass.
[0207] Figure 8 illustrates a method according to an embodiment of the invention, wherein processing steps are performed. In this embodiment, the processing steps include applying a detergent. As can be seen from the top, the aggregated analyte binds to the first molecular recognition element 10. The corresponding increase in signal is visible during time intervals 2 to 4. Then, in time interval 5, a detergent is applied that removes some or all of the analyte (see middle section). The signal decreases due to the loss of mass interacting with the first molecular recognition element 10. The measured signal can typically be further included in the immunoassay of the protein disease analyte and / or biofluid sample. If, for example, certain analytes are known to be sensitive to different treatments (such as detergents, pH, etc.), such treatment steps can be used to provide further information about the analyte associated with the protein disease.
[0208] Figure 8 depicts an embodiment of the method according to the invention, wherein a seed amplification assay is performed after step b. As can be seen at the top of Figure 8, the biofluid sample contains analyte 13 associated with the protein disease. After providing the biofluid sample, a protein sample containing monomeric protein 15 is added to the sample containing the first pattern element 8 and the secondThe corresponding identification pattern of pattern element 9. Since the analyte 13 associated with the protein disease exhibits, for example, prion-like behavior, it affects the misfolding and aggregation of the added monomeric protein. Therefore, it can be seen from the middle part of FIG8 that aggregation increases and additional aggregates are formed. Seed amplification can be observed in real time since the increase in mass due to the advancement of aggregation can be directly measured. This is shown in the lower part of FIG8, showing the measured signal over time. It can be seen that the measured signal increases continuously during time interval 2, which directly indicates that seed amplification is occurring.
[0209] FIG9 shows an embodiment of the method according to the invention, wherein the sensing device (not shown) includes a plurality of identification patterns 5'a, 5''a, 5'b, 5''b, 5'c, 5''c, 5'd and 5''d. Each identification pattern includes a first pattern element (with a first molecular identification element associated thereto) and a second pattern element (with a second molecular identification element associated thereto). Preferably, in this embodiment or any other embodiment described herein, at least some or even all of the identification patterns may include a unique first molecular identification element and / or a unique second molecular identification element. The terms "unique" or "specific" in this context mean that the first (or second) molecular recognition element of a particular identification pattern is different from the first (or second) molecular recognition element of other identification patterns of the sensing device; however, the first molecular recognition element within each identification pattern is typically the same. As can be seen from the graph depicting the time-dependent measured signals, each identification pattern acquires a signal once the biofluid sample S is provided to it. These signals can then all represent parameters in a high-dimensional vector space, as shown in matrices a11 to a43. In this embodiment or any other embodiment described herein, this parameter matrix can be an immune signature of the biofluid sample and / or analytes associated with protein diseases that have been screened using the method according to the invention. This immune signature can then be compared by the control unit 4, including processor 41, with a database stored in the memory 42 of the control unit 4. If the database subsequently contains data associated with the clinical status of the proteinopathy in patient samples, autologous patient samples (i.e., samples from previously screened patients who have obtained currently screened biofluid samples), and / or reference samples, the nature of the proteinopathy associated with the analyte and / or clinical status can be characterized. Furthermore, the progression of the proteinopathy can be predicted. Additionally, other parameters, such as one or more signals obtained from the seed amplification assay described herein or from the addition of the quality-labeled binder described herein, can also be included in the immune signature.
[0210] Figures 10a and 10bAn embodiment of the method according to the invention is illustrated, wherein multiple recognition patterns of the sensing device compete for an analyte associated with a protein disease. Both Figures 10a and 10b illustrate continuous competitive measurements, with arrows indicating the flow direction of the biological fluid sample. That is, in Figure 10a, the biological fluid sample is provided such that it first contacts two recognition patterns 5'a, 5''a, then two recognition patterns 5'b, 5''b, and then two recognition patterns 5'c, 5''c. If, for example, the first two recognition patterns 5'a, 5''a include a first molecular recognition element having a binding site A, the middle two recognition patterns 5'b, 5''b include different first molecular recognition elements having a binding site B, and the last recognition pattern 5'c, 5''c includes yet another different first molecular recognition element having a binding site C, then the behavior of the analyte 13 associated with the protein disease, which binds to these different first molecular recognition elements 10, can provide valuable information about the analyte 13 and the protein disease. Figure 810 illustrates a sequential competitive measurement of the same sensing device as shown in Figure 10a, however, with the flow direction reversed. Performing such sequential competitive measurements, i.e., a first measurement with a first flow direction and a second measurement with a reverse flow direction, provides additional information that allows for further characterization of analyte 13 and the protein pathogenesis.
[0211] Figure 11 illustrates parallel measurements. It can be seen that the sensing device includes three sets of recognition patterns, each set comprising two recognition patterns. The first set includes recognition patterns 5'a, 5''a with a first molecular recognition element having a binding site A. The second set includes recognition patterns 5'b, 5''b with a first molecular recognition element having a binding site B. The third set includes recognition patterns 5'c, 5''c with a first molecular recognition element having a binding site C. The sensing device includes wall structures 12 that separate the sets of recognition patterns from each other. In this embodiment or any other embodiment, the wall structures 12 may form channels, such as microfluidic channels, which are part of the fluid system of the sensor chip. It can be seen that a biofluid sample can be provided to the sensing device upstream of the recognition patterns. It then flows parallel through each recognition pattern. Due to the presence of the wall structure 12, the biofluid sample cannot flow from one channel to another.
[0212] Figure 12 illustrates another embodiment of the method according to the invention. It can be seen that the recognition pattern of the sensing device used includes a first molecular recognition element 10 coupled to a first pattern element 8, each first molecular recognition element including two distinct binding sites A and B. This is advantageous because it allows for more accurate characterization of the analyte 13, which expresses complementary binding sites and / or epitopes on its surface.a and b. For certain protein diseases, it is known that cellular remnants such as mitochondria or portions thereof are recruited and form aggregates. Furthermore, it is known that such mitochondria or portions thereof may contain specific marker proteins, such as protein b, for example, VDAC. Therefore, by utilizing this knowledge, the properties or composition of analyte 13 can be further characterized by equipping the first molecular recognition element 10 with a binding site A that binds to a specific binding site on the marker and / or epitope a and a binding site B that specifically binds to mitochondrial protein b.
[0213] Figure 13 illustrates a principle similar to that of Figure 12, but in this case, lysosomes are part of the specific exposed surface protein c of analyte 13, such as LAMP1. Therefore, if the first molecular recognition element 10 contains a binding site C configured to bind to protein c, further details about the composition of analyte 13 and the nature of the associated protein disease can be provided.
[0214] Figure 14 illustrates another variant similar to the examples shown in Figures 12 and 13. In this case, protein co-aggregates are screened as analyte 13 associated with the protein disease. In this variant, for example, it can be assumed that the patient suffers from a specific proteopathic disease involving protein aggregates with a specific post-translational modification d. By using a sensing device having at least one identification pattern with a first identification element, each of which includes two binding sites A and D, wherein the latter is specific for the post-translational modification d, information about the nature of the proteopathic disease (and correspondingly, the analyte 13 associated with the proteopathic disease) can be generated.
[0215] Figure 15 illustrates a method 100 for screening a biological fluid sample for an analyte according to an embodiment of the invention. Method 100 includes multiple steps S1 to S5. Method 100 is performed using a sensing device 10 as described herein. Specifically, at least one step in this process is performed using a sensing device. Method 100 may be performed at a location (e.g., a laboratory or analytical facility). Method 100, or in particular one or more steps of method 100, may alternatively be performed at separate locations, as described in detail below.
[0216] In step S1, a sensor chip is provided. The sensor chip includes a recognition pattern having molecular recognition elements as described herein. Depending on the implementation of the method, the sensor chip may be sent or otherwise provided to a third party, enabling the third party to apply a biological fluid sample as described below.
[0217] In step S2, a sensing device is provided. The sensing device includes an imaging microscopy apparatus. Imaging microscopy apparatusThe sensor chip is configured to image the sensor chip, thereby recording image data. The sensor chip can be imaged in one or more states. For example, the sensor chip can be imaged without any biological fluid sample being applied. The sensor chip can be imaged at one or more time points after the biological fluid sample has been applied, thereby recording image data including the analyte.
[0218] In step S3, a sensor chip with bound analyte is obtained. In optional step S31, the biological fluid sample can be applied to the sensor chip as part of the method. The biological fluid sample can be applied to the sensor chip when the sensor chip is actively imaged / recorded by the sensing device. Thus, time-series image data at multiple time points can be obtained, thereby allowing dynamic adsorption of the analyte by the recorded sensor chip. Alternatively, the biological fluid sample can be previously applied, and the sensing device records the sensor chip once the analyte has been maximally adsorbed onto the sensor chip.
[0219] In step S4, the sensor chip is imaged using an imaging microscopy device. The obtained image data can be stored, transmitted, or further processed by the sensing device itself.
[0220] In step S5, the recorded image data is used to quantize the quality modulation contrast. Step S5 can be performed by the sensing device itself or by another device that receives imaging data from the sensing device.
[0221] Quantization of the image data can include filtering the image data to obtain improved image data. The image data can be filtered by comparing the recording of the sensor chip with the analyte with the image data of the sensor chip without the analyte. Thus, the sensor chip (especially the quality modulation that is already present on the sensor chip due to the recognition pattern) can be filtered out.
[0222] Figure 16 shows a flowchart illustrating a method for screening biological fluid samples for analytes. In particular, the figure illustrates the principle of digital lock-in amplification. A binary model grating is generated with vertical lines (top). Fourier analysis (bottom) reveals the amplitude spectrum in the reciprocal space (embedded at the bottom). The periodicity, symmetry, orientation, and amplitude of the grating reveal the Fourier components. The line cross-section plot at the bottom illustrates the Fourier components of the one-dimensional grating (i.e., the grating is periodic only in a single dimension). The main peak in the Fourier spectrum corresponds to the grating spacing. Higher-order peaks appear at multiples of the grating spacing.
[0223] This figure shows image data in real space and reciprocal space for a simple recognition pattern. The recognition pattern includes ridges and grooves. The ridges and grooves can be mass modulation (i.e., physical ridges and grooves) or optical ridges and grooves, i.e., small variations in the optical properties (e.g., refractive index) of the surface.
[0224] Figure 17 shows the same recognition pattern shown in Figure 16, however, where the black dots indicate that selective...The analyte is attached or adsorbed to the sites in the grooves (white lines). Since the molecular recognition element is only present in the grooves, the analyte is only bound to the grooves. The black dots thus completely and selectively hide the white pattern elements, reducing the overall white grating area. The amplitude-spectrum (bottom) still reveals the same Fourier components as in Figure 16, but the amplitude is reduced, which is particularly noticeable in the reduced amplitude of the first peak.
[0225] It is clear that the effect or signal of the black dots can be separated by comparing (filtering) the Fourier spectrum obtained by using the Fourier spectrum obtained in the absence of any analyte (black dots). Therefore, the mass modulation of the black dots can be quantified.
[0226] Figure 18 shows the same recognition pattern as shown in Figures 16 and 17, however, in addition to the black dots representing the analyte, another white line has been randomly drawn above the recognition pattern. The white line indicates other parts of the biofluid sample that adhere to the recognition pattern. Other portions adhere nonselectively, meaning they randomly cover both grooves and ridges, and are therefore approximately equal, since the other portions do not bind to the molecular recognition element. The nonselective reduction in grating area due to the other portions results in a random reduction in the white and black patterned elements, which has a much smaller effect on the amplitude of the grating Fourier components than the selective reduction of the white grating elements (even if the reduced grating area is an order of magnitude larger (top)), as shown in Figure 17. As can be seen from the Fourier spectrum (bottom), the peak amplitude (especially the peak amplitude of the first Fourier component) does not change significantly due to the presence of other portions on the recognition pattern. This indicates that the technique is robust to the presence of randomly adhered particles.
[0227] Figure 19 shows an illustration of a DNA origami structure functionalized with the molecular recognition element a as described herein. The recognition grating has a scale on the nanometer scale. The basic working principle of DNA origami biosensors is described in the following literature: Wang S, Zhou Z, Ma N, Yang S, Li K, Teng C, Ke Y, Tian Y. DNA Origami-Enabled Biosensors. Sensors (Basel). 2020 Dec 3;20(23):6899. doi: 10.3390 / s20236899. PMID: 33287133;PMCID: PMC7731452.
[0228] These DNA origami microstructures can be imaged in a label-free manner using atomic force and electron microscopy. Invented about 30 years ago, today's DNA origami concept allows us to organize DNA in a programmed manner in both planar and spatial dimensions. At the bottom is DNAScaffolding chains (continuous lines) are incubated together with a series of complementary staple chains (dashed lines) to give a well-defined pattern.
[0229] The staple chains may be equipped with extensions or connector elements. Molecular recognition elements a, as described herein, can be attached to the connector elements to produce a spatially organized recognition pattern.
[0230] These extensions or connector elements can be implemented as single strands of DNA with a specific sequence. Furthermore, it is possible to couple recognition elements directly to specific staple chains. The latter has the advantage of less spatial uncertainty because the connector elements are shorter, and therefore the molecular recognition elements can be arranged closer to the staple chains.
[0231] Patterns of the type shown are well suited for analysis in Fourier space (see Figure 20).
[0232] Vectors e(y) and e(x) represent the unit cell vectors of the pattern formed by the molecular recognition elements a. Although there are some variations in the exact position of element a relative to the unit cell vectors, Fourier analysis reveals that the fundamental Fourier components are large enough to be used with such gratings as described herein.
[0233] Figure 20 shows an illustration of the recognition pattern (top left) including the DNA origami structure described above with reference to Figure 19. Fourier analysis (top right) shows the frequency components of the recognition pattern as highlights. The circular dominant frequency components, when transformed back into real space, reveal the unit cell vectors in the form of a two-dimensional pattern, thus showing that the recognition pattern is suitable for use in the invention. In particular, 2D spectroscopy is able to monitor multiple amplitude modulations associated with selective variations that are related to in-plane grating symmetry. The modulations affecting different symmetry vectors of the unit cell can be analyzed independently and can therefore be used to filter modulations associated with independent frequencies, symmetry, and orientations.
[0234] Figure 21 shows a recognition pattern similar to the recognition pattern described above with reference to Figures 19 and 20, which includes various different types of molecular recognition elements a, b, and c. In this way, the DNA origami structure is functionalized to create a multiplexed biosensor with nanometer resolution. The digital lock-on magnification principle is applied to photomicrographs recorded by atomic force or electron microscopy, which allows for filtering and differentiation of amplitude modulation at different recognition sites along the grating.
[0235] In other words, different types of molecular recognition elements a, b, c can be combined with different analytes. Therefore, the same recognition pattern can be used to detect a variety of different analytes.
[0236] Preferably, the spatial frequencies of the pattern formed by the molecular recognition elements a, b, c are different, such that the Fourier components (especially the principal Fourier components) do not overlap.
[0237] For example, the single-frequency components of the unit cell are spatially organized in terms of symmetry and dimensionality to follow a sequence =1 / n; the Fourier components of the unit cell obtained by n = 1, 2, 3, 5, 7, 11, 13, 17 (such as prime numbers, and as shown on the right) are unlikely to superimpose or become multiples of each other; therefore, different recognition sites can be monitored / filtered extensively and independently. This concept is also applied to microstructures.
[0238] More generally, the unit cell vectors of the pattern formed by each of the different types of molecular recognition elements a, b, c in the recognition pattern do not have a common denominator. In other words, the prime factorization does not share any prime numbers. Therefore, the principal Fourier components do not coincide.
[0239] Figure 22 shows exemplary relative spatial frequencies between different types of molecular recognition elements a, b, c, where molecular recognition element a has a relative spatial frequency of 1 / 5, molecular recognition element b has a relative spatial frequency of 1 / 3, and molecular recognition element c has a relative spatial frequency of 1 / 7.
[0240] Figure 23 shows an electron microscope image of the sensor chip. Multiple identification patterns exist, each implemented as a rectangular DNA origami structure. The overall size of the sensor chip is approximately 5 x 5 micrometers. It can be seen that each origami structure has a size on the order of 100 nm.
[0241] Electron microscope images can be analyzed to identify the identification patterns using pattern matching or other image analysis tools. The identification patterns can then be superimposed to improve the signal-to-noise ratio. In particular, the identification patterns are identified and then rotated as needed so that they are aligned with each other. The images can then be added to / superimposed on each other to improve the signal-to-noise ratio for further analysis in Fourier space.
[0242] In one embodiment, each identification pattern has a reference marker attached at a specific point (as shown by a white dot in one of the magnified insert images). For example, the reference marker can be a metal nanoparticle. The reference marker allows the detection of the position and orientation of the identification pattern, even if the electron microscope image has an overall low contrast level.
[0243] The insert image where the arrow points to the reference marker is a superimposed image of other identification patterns that have been rotated and added to each other. In one embodiment, the sensor chip may include multiple sets of recognition patterns, each with a different molecular recognition element. Thus, a single sensor chip can be functionalized to detect multiple different analytes. Each set of recognition patterns may have different features, allowing them to be distinguished from one another. For example, each set may have recognition patterns of different shapes or sizes. In another instance, each set may have different reference markers, or reference markers attached at different points (e.g., along an edge or at a corner).
[0244] List of Names 1 Screening Device 10 Sensing Device 100 White Light Interferometer (WLI) 101 Camera 102 Reflective Surface Description Pages 35 / 3641 CN 121969891 A 103 Tricolor LED 104 Beam splitter 105 Reference plane 110 Vertical scanning white light interferometer (VSWLI) 2 Imaging microscopy equipment, imaging unit 3 Sensor chip 4 Control unit 41 Processor 42 Memory unit 5 Recognition pattern 5'a, 5"a Recognition pattern 5'b, 5"b Recognition pattern 5'c, 5"c Recognition pattern 5'd, 5"d Recognition pattern 6 Light source 7 Detector, optical image detector 8 First pattern element 9 Second pattern element 10 First molecular recognition element 11 Second molecular recognition element 12 Wall structure 13 Protein analyte 14 Quality-labeled binder 15 Monomeric protein. Instruction manual page 36 / 36, page 42, CN 121969891 A, Figure 1; Instruction manual figure 1 / 24 page, page 43, CN 121969891 A, Figure 2a; Instruction manual figure 2 / 24 page, page 44, CN 121969891 A, Figure 2b; Instruction manual figure 3 / 24 page, page 45, CN 121969891 A, Figure 2c; Instruction manual figure 4 / 24 page, page 46, CN 121969891 A, Figure 2d; Instruction manual figure 5 / 24 page, page 47, CN 121969891 A, Figure 3a; Instruction manual figure 3b; Instruction manual figure 6 / 24 page, page 48, CN 121969891 A, Figure 3c; Figure 4; Instruction manual figure 7 / 24 page, page 49, CN 121969891 A, Figure 5a; Instruction manual figure 8 / 24 page, page 50, CN 121969891 A, Figure 5b; Instruction manual figure 9 / 24 page, page 51, CN Figure 6 of the instruction manual, page 10 / 24, CN 121969891 A; Figure 7 of the instruction manual, page 11 / 24, CN 121969891 A; Figure 8 of the instruction manual, page 12 / 24, CN 121969891 A; Figure 9 of the instruction manual, page 12 / 24, CN 121969891 A; Figure 10a of the instruction manual, Figure 10b of the instruction manual, page 13 / 24, CN 121969891 A; Figure 12 of the instruction manual, page 14 / 24, CN 121969891 A; Figure 13 of the instruction manual, page 15 / 24, CN 121969891 A; Figure 14 of the instruction manual, page 16 / 24, CN 121969891 A; Figure 15 of the instruction manual, page 17 / 24, CN 121969891 A; Figure 16 of the instruction manual, CN 121969891 AInstruction manual illustrations, pages 18 / 24, number 60, CN 121969891 A, Figure 17; Instruction manual illustrations, pages 19 / 24, number 61, CN 121969891 A, Figure 18; Instruction manual illustrations, pages 20 / 24, number 62, CN 121969891 A, Figure 19; Instruction manual illustrations, pages 21 / 24, number 63, CN 121969891 A, Figure 20; Instruction manual illustrations, pages 22 / 24, number 64, CN 121969891 A, Figure 21; Instruction manual illustrations, pages 23 / 24, number 65, CN 121969891 A, Figure 23; Instruction manual illustrations, pages 24 / 24, number 66, CN 121969891 A.
Claims
1. A method for screening a biological fluid sample for an analyte, preferably a single analyte or a mixture of analytes associated with a protein disease, the method comprising the steps of: a. Provide a sensor chip (3) comprising an identification pattern (5) extending in a two-dimensional plane and having patterned elements (8) arranged thereon, at least some of the patterned elements (8) being functionalized by a molecular identification element (10) for binding an analyte (13), the identification pattern (5) having a characteristic spatial spectrum in the plane; b. Provide a sensing device (10), which is or includes an imaging microscopy device (2) configured to detect a measurement signal indicating the identification pattern (5); c. Obtain the sensor chip (3), which has been coated with at least a portion of the analyte (13) of the biological fluid sample; d. Image at least a portion of the recognition pattern (5) to obtain image data as a function of one or two spatial measurement coordinates in the plane, digitize the image data, and determine Fourier transform image data as a function of one or two corresponding spatial frequency coordinates; e. Improved Fourier transform image data is determined by filtering the Fourier transform image data using the feature space spectrum of the recognition pattern (5); as well as f. The improved Fourier transform image data is re-transformed into direct space to obtain improved image data, and thereby the quality modulation contrast generated by the immobilized analyzer (13) is quantified.
2. The method according to claim 1, wherein obtaining the sensor chip (3) with at least a portion of the analyte (13) applied thereon comprises providing the biofluid sample to the sensor chip (3) such that at least a portion of the analyte (13) is fixed at at least some of the molecular recognition elements (10, 11) thereby modifying the measurement signal.
3. The method according to any one of the preceding claims, wherein the pattern element (8) comprises a first pattern element (8) and a second pattern element (9), particularly ridges and grooves, and at least one of the first pattern element and the second pattern element (8, 9) is functionalized by the molecular recognition element (10, 11).
4. The method according to any one of the preceding claims, wherein the identification pattern (5) comprises a plurality of pattern elements (8) of different types, each type of pattern element (8) having different spatial periodicity and / or symmetry, such that the identification pattern (5) has a plurality of corresponding feature spatial spectra in the plane.
5. The method according to any one of the preceding claims, wherein the characteristic spatial spectrum of the identification pattern (5) includes at least one peak region, the at least one peak region representing the pattern wavelength and / or pattern shape of the identification pattern (5).
6. The method according to any one of the preceding claims, wherein the pattern wavelength of the identification pattern (5) is selected to be shorter than the typical distance between spatial noise components of substances present in or arbitrarily combined with the identification pattern in the biological fluid sample.
7. The method according to any one of the preceding claims, wherein the identification pattern (5) is formed at least in part by a periodically repeating DNA origami structure comprising scaffold chains and staple chains, the DNA origami structure providing the pattern element (8).
8. The method of claim 7, wherein the molecular recognition element is connected to the staple chain via a connector element or an oligonucleotide.
9. The method according to any one of claims 7 or 8, wherein the DNA origami structure comprises at least two different types of molecular recognition elements, and particularly wherein the at least two different types of molecular recognition elements have different spatial periodicity and / or symmetry.
10. The method according to any one of the preceding claims, wherein in step e, the improved Fourier transform image data is determined by low-pass filtering, high-pass filtering, or band-pass filtering to discard spatial noise components outside at least one peak region of the characteristic spatial spectrum of the identification pattern (5).
11. The method according to any one of the preceding claims, wherein the identification pattern (5) has the first pattern element (8) and alternating second pattern elements (9), the first pattern element (8) being selected from: lines of functionalized sites that are repeatedly offset in the lateral direction; straight lines or curves of functionalized sites that are repeatedly offset in the lateral direction; an array of dotted functionalized sites; and combinations thereof; the second pattern element (9) being selected from: lines of gap sites; straight lines or curves of gap sites; an array of dotted gap sites; and combinations thereof.
12. The method according to any one of the preceding claims, wherein the height and / or refractive index of the identification pattern (5) is modified when the analyte is fixed.
13. The method according to any one of the preceding claims, wherein the imaging microscopy device (2) is selected from: white light interferometer (WLI), scanning probe microscope (SPM), especially atomic force microscope (AFM) or scanning tunneling microscope (STM), electron microscope, confocal microscope, especially laser scanning confocal microscope (LSCM), infrared microscope, Raman spectrometer, phase contrast microscope and combinations thereof.
14. The method according to any one of the preceding claims, wherein in step a. the method provides a multiplexed sensor chip (3), the multiplexed sensor chip (3) comprising a plurality of identification patterns (5), the plurality of identification patterns (5) preferably arranged at different locations on the sensor chip (3), and in particular, a particular identification pattern (5) is characterized by at least one of the following: a particular functionalization of at least one first pattern element or a second pattern element (8, 9) for combining one or more particular analytes (13); a particular feature spatial spectrum in the plane; a particular positioning of the identification pattern (5) on the sensor chip (3); a particular arrangement of the identification pattern on the sensor chip (3), for example, in a rectangular or square array.
15. The method according to any one of the preceding claims, wherein the imaging microscopy device (2) is a white light interferometer (WLI), the white light interferometer operates under reflection and includes an imaging detector having a linear or planar pixel array, the imaging detector being configured to acquire interferometric image data containing phase-sensitive information for determining the height and / or refractive index distribution of the identification pattern (5) and thereby determining the mass modulation generated by the immobilized analyte (13).
16. The method according to any one of the preceding claims, wherein the imaging microscopy device (2) is a scanning probe microscope, such as a scanning force microscope, the scanning probe microscope comprising a cantilever or cantilever array configured to perform contour analysis on the plane to obtain AFM image data containing AFM feature information for determining the atomic or molecular height contours of the pattern and thereby determining the mass modulation generated by the immobilized analyte (13).
17. The method according to any one of the preceding claims, wherein the functionalization is based on: the molecular recognition element, in particular the antibody, providing chemical specificity to bind at least one specific analyte (13) associated with a protein disease, and / or being configured to bind a specific epitope of the analyte (13) associated with a protein disease, and / or being configured to bind the analyte or the epitope of the analyte associated with the protein disease with specific binding affinity.
18. The method according to any one of the preceding claims, wherein the first pattern element (8) is configured to incorporate a first analyte, the second pattern element (9) is configured to incorporate a second analyte, and the sensing device (10) is configured to quantify the difference between the quality modulation contrast generated by immobilizing the first analyte and the immobilizing the second analyte.
19. The method according to any one of the preceding claims, the method further comprising the following steps: The parameters of the analyte (13) associated with the protein disease were determined from the quantified quality modulation contrast and, optionally, time. And / or determine parameters of the following from the quantified quality modulation contrast and optionally time: aggregates of the analyte (13) associated with the protein disease, or co-aggregates containing the analyte (13) associated with the protein disease.
20. The method of claim 19, further comprising the following steps: The presence of the aggregate or co-aggregate is determined from determined parameters, particularly if the determined parameters exceed a predetermined threshold within a predefined incubation time; and preferably, determining the presence of the aggregate or co-aggregate includes comparing the determined parameters with reference parameters, such as reference parameters obtained from different patient groups or from healthy subjects, or previous parameters of subjects from whom the biofluid sample has already been obtained.
21. The method according to any one of the preceding claims, wherein the analyte associated with the protein disease comprises one or more of the following: β-amyloid protein, tau, α-synuclein, prion protein, sarcoma fusion protein, wild-type or mutant polyQ huntingtin protein, ubiquitin, ataxin-3, Optineurin, TAR DNA-binding protein 43, neurofibrillary light chain (NfL), soluble or exfoliated trigger receptor 2 (sTREM2) expressed on myeloid cells, chitinase-3-like protein 1, glial fibrillary acidic protein, and truncated or other post-translational modified forms of these proteins.
22. The method according to any one of the preceding claims, wherein step d. is performed during a measurement time, and the image data is measured as a function of the measurement time to determine aggregation behavior, particularly the aggregation of additional material in the biofluid sample, such as any residual biological material, for example, cellular components, mitochondria, cell membranes, nucleic acids, proteins, and fragments thereof; or step d. includes single-point measurements at specific time points, particularly steady-state measurements.
23. The method according to any one of the preceding claims, wherein a rinsing step is performed after step c, and particularly before or during step d, and / or wherein a treatment step is performed after step b, the treatment step preferably comprising applying a treatment agent, such as a detergent, selected from: ionic agents, solvents, acids, bases, aggregate stabilizers, aggregate destabilizers, and combinations thereof.
24. The method according to any one of the preceding claims, wherein after step b, seed amplification assay is performed by adding a binding reagent sample, particularly a protein sample, to the identification pattern (5).
25. The method according to any one of the preceding claims, wherein the method further comprises a secondary characterization step for characterizing the state of the analyte (13) associated with the protein disease or aggregates or co-aggregates formed by the analyte (13) associated with the protein disease, wherein the secondary characterization step preferably comprises ELISA, FT-IR, Raman or fluorescence spectroscopy; particularly wherein the secondary characterization step is performed directly on the biofluid sample already provided to the identification pattern (5).
26. The method according to any one of the preceding claims, wherein the signals measured in steps c. and d. form an immune signature of the biofluid sample; particularly wherein the immune signature of the biofluid sample is compared with a database of immune signatures comprising a plurality of samples, such as patient samples, autologous patient samples and / or reference samples, wherein the immune signatures in the database are preferably each associated with a clinical state of a protein disease.
27. A screening apparatus (1) for screening biological fluid samples for analytes, particularly an apparatus (1) for performing the method according to any one of the preceding claims, said apparatus (1) comprising: a. A sensor chip (3) comprising an identification pattern (5) extending in a two-dimensional plane and having patterned elements arranged thereon, at least some of the patterned elements (8) being functionalized by a molecular identification element (10) for binding an analyte (13), the identification pattern (5) having a characteristic spatial spectrum in the plane; b. A sensing device (10), which is or includes an imaging microscopy device (2) configured to detect a measurement signal indicating the identification pattern (5) and to detect a modified measurement signal that has been modified because at least a portion of the analyte (13) of the biological fluid sample has been applied thereon to the sensor chip; c. The sensing device (10) includes: an imaging unit (2) for imaging at least a portion of the identification pattern (5) to obtain image data as a function of one or two spatial measurement coordinates in the plane; and a processor (41) configured to digitize the image data and to determine Fourier transform image data as a function of one or two corresponding spatial frequency coordinates. d. The sensing device (10) further includes: a processor (41) configured to improve the Fourier transform image data by filtering the Fourier transform image data using the feature space spectrum of the recognition pattern (5); and e. The processor (41) is configured to retransform the improved Fourier transform image data into direct space to obtain improved image data, and is configured to thereby quantify the quality modulation contrast generated by the immobilized analyte.
28. The screening device (1) according to claim 27, wherein the sensing device (10) further comprises a sampling unit for providing the biofluid sample to the sensor chip (3) such that the portion of the analyte (13) is fixed at at least some of the molecular recognition elements (8, 9) to modify the measurement signal.
29. The screening device (1) according to any one of claims 27 or 28, wherein the pattern element (8) comprises a first pattern element (8) and a second pattern element (9), particularly ridges and grooves, at least one of the first pattern element and the second pattern element (8, 9) being functionalized by the molecular recognition element (10, 11).
30. The screening device (1) according to any one of claims 27 to 29, wherein the identification pattern (5) comprises a plurality of pattern elements (8) of different types, each type of pattern element (8) having a different spatial periodicity, such that the identification pattern (5) has a plurality of corresponding feature spatial spectra in the plane.
31. The screening device (1) according to any one of claims 27 to 30, wherein the processor (41) is configured to filter the Fourier transform image data for relative enhancement in a selected region, particularly in a narrow spatial frequency range, wherein the pattern of the identification pattern (5) has characteristic spatial frequency peaks representing the pattern period and / or pattern shape of the identification pattern (5).
32. The screening device (1) according to any one of claims 27 to 31, wherein on the sensor chip (3), the pattern wavelength of at least one identification pattern (5) is selected to be shorter than the typical distance between the spatial noise components of the material present in or arbitrarily combined with the identification pattern (5) in the biological fluid sample.
33. The screening device (1) according to any one of claims 27 to 31, wherein the identification pattern (5) is formed at least in part by a periodically repeating DNA origami structure comprising scaffold chains and staple chains, the DNA origami structure providing the pattern element (8).
34. The screening device (1) according to claim 33, wherein the molecular recognition element is connected to the staple chain via a connector element.
35. The screening device (1) according to any one of claims 33 or 34, wherein the DNA origami structure comprises at least two different types of molecular recognition elements, and in particular, wherein the at least two different types of molecular recognition elements have different spatial periodicity.
36. The screening device (1) according to any one of claims 27 to 35, wherein the identification pattern (5) has the first pattern element (8) and has alternating second pattern elements (9), the first pattern element (8) being selected from: lines of functionalized sites that are repeatedly offset in the lateral direction; straight lines or curves of functionalized sites that are repeatedly offset in the lateral direction; an array of dotted functionalized sites; and combinations thereof; the second pattern element (9) being selected from: lines of gap sites; straight lines or curves of gap sites; an array of dotted gap sites; and combinations thereof.
37. The screening device (1) according to any one of claims 27 to 36, wherein the sensor chip (3) is multiplexed to include a plurality of identification patterns (3), the plurality of identification patterns preferably being arranged at different locations on the sensor chip (3), and in particular, a particular identification pattern (5) is characterized by at least one of the following: specific functionalization of at least one first pattern element or second pattern element (8, 9) for combining one or more specific analytes (13); a specific feature spatial spectrum in the plane; a specific positioning of the identification pattern (5) on the sensor chip (3); a specific arrangement of the identification pattern (5) on the sensor chip (3), for example, in a rectangular or square array.
38. The screening apparatus (1) according to any one of claims 27 to 37, wherein the imaging microscopy device (2) is a white light interferometer (WLI), the white light interferometer operates under reflection and includes an optical imaging detector having a linear or planar pixel array, the optical imaging detector being configured to acquire interferometric image data containing phase-sensitive information for determining the height and / or refractive index distribution of the identification pattern (5) and thereby determining the mass modulation generated by the immobilized analyte (13).
39. The screening apparatus (1) according to any one of claims 27 to 38, wherein the imaging microscopy device (2) is a scanning atomic force microscope (AFM) comprising a cantilever or array of cantilever arms configured to scan across the plane to obtain AFM image data containing AFM feature information for determining the atomic or molecular height profile of the identification pattern (5) and thereby determining the mass modulation generated by the immobilized analyte (13).
40. A sensor chip (10) specifically intended for use with a screening device (1) according to any one of claims 27 to 39 or for use in a method according to any one of claims 1 to 26, the sensor chip comprising a recognition grating comprising a DNA origami structure functionalized with molecular recognition elements for binding analytes, the molecular recognition elements forming substantially periodic patterns.
